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ABSTRACT 
Human YVH1 (hYVH1, also known as DUSP12) is a poorly-characterized atypical 
dual-specificity phosphatase widely expressed in human tissues.  The yvh1 gene is 
evolutionarily conserved and all orthologues possess an N-terminal dual specificity 
phosphatase domain and a novel C-terminal zinc-binding domain (ZBD). We developed a 
low-pH thiol-labeling and enrichment strategy coupled to mass spectrometry for 
characterizing thiol oxidation by mass spectrometry.  Employing this method, we provide 
further evidence that hYVH1 utilizes a disulfide exchange mechanism to regulate its 
activity under oxidative environment.    
Moreover, we have identified hYVH1 to be associated with various 
ribonucleoprotein particles using affinity chromatography coupled to mass spectrometry 
employing ion mobility separation.  Of particular importance, hYVH1 was confirmed to 
associate with mRNP particles containing Y-box-binding protein 1 (YB-1) and fragile X 
mental retardation protein (FMRP), proteins that function in translational repression and 
stress granule regulation.  Follow-up microscopy studies demonstrated that hYVH1 
overexpression reduces stress granule size, while knocking down hYVH1 expression 
attenuated stress granule breakdown during recovery from arsenite stress, implicating 
hYVH1 as a novel stress granule disassembly factor.    
Structural mass spectrometry experiments were conducted to gain insight into the 
hYVH1 topology landscape as a first step towards mapping regions mediating RNP 
association. Pro272, Trp275 and Met276 within the ZBD were predicted to be solvent exposed 
by in silico prediction modeling and hydrogen/deuterium exchange mass spectrometry 
(HDX-MS) analysis. Site-directed mutagenesis revealed that these three highly conserved 
viii 
 
amino acids moderately affect stress granule dynamics. In addition, HDX-MS results 
showed that residues 160-189 located in the linker region are highly solvent accessible.  
Furthermore, limited proteolysis experiments demonstrated this region to be inaccessible 
to proteolysis only under oxidative conditions suggesting that this region undergoes 
dynamic conformational changes during hYVH1 oxidation. Taken together, a variety of 
mass spectrometry based techniques have advanced the understanding of hYVH1 in RNP 
dynamics and discovered putative regions of structural importance for how hYVH1 
functions in cellular regulation. 
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CHAPTER 1  
Literature Review 
1.1 Cellular Protein Phosphorylation 
Protein phosphorylation was discovered in the 1950s by Eddy Fischer and Ed 
Krebs. Phosphorylation is a reversible post-translational modification (PTM) and plays a 
very important role in cell differentiation, cell cycle regulation, and metabolism (1-4). 
Protein phosphorylation most commonly occurs on the hydroxyl groups of serine, 
threonine, and tyrosine residues. Proteomic analysis reveals that the distribution of 
phosphoserine (pSer), phosphothreonine (pThr), and phosphotyrosine (pTyr) is 86.4%, 
11.8%, and 1.8% respectively in 2244 human proteins; however, other residues like 
arginine, cysteine, and lysine can also be phosphorylated (5,6). By adding a negatively 
charged phosphate group on one or multiple residues, the conformation of proteins will 
change and result in alternate enzymatic activity, cellular localization, and protein-protein 
interactions, altering protein function and consequently cellular signaling pathways 
(Fig.1.1) (7).  
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Figure 1. 1. Reversible protein phosphorylation acts as a regulatory switcher in cells. 
Protein phosphorylation is under control of protein kinases and protein phosphatases to 
regulate protein cellular localization, enzymatic activity, protein turnover, protein-protein 
or protein-ligand binding, protein conformation, and crosstalk with other PTMs. Modified 
from Humphrey, et al (2015) (8). 
  
3 
 
It is reported that one in every three eukaryotic proteins is phosphorylated (9). The 
dynamics of protein phosphorylation and dephosphorylation (the act of removing a 
phosphate group) in cells is under the strict control of numerous protein kinases and protein 
phosphatases (10,11). Interestingly, the catalytic activities of protein kinases and 
phosphatases are often controlled by reversible phosphorylation. For example, cyclin-
dependent kinases (CDKs) which are regulatory enzymes that participate in the eukaryotic 
cell cycle, are tightly regulated by reversible phosphorylation (12). The kinase activity of 
CDKs not only requires cyclin association, but also threonine phosphorylation (human 
CDK2 requires Thr160 phosphorylation) (13,14). Furthermore, the enzymatic activity of 
mitogen-activated protein kinase (MAPK) is drastically decreased if it is treated with a 
phosphatase (up to 86%) (13,15,16). Src family tyrosine kinases (SFKs) are also under 
control of phosphorylation where two conserved tyrosine residues (Tyr416 and Tyr 527) 
require phosphorylation for activation (17). Phosphatases are also tightly regulated by 
phosphorylation. For example, phosphorylation of Ser566 by protein kinase A (PKA) 
positively regulates the activity of protein phosphatase 2A (PP2A) (18). 
As shown in Fig.1.2, protein kinases are responsible for catalyzing the transfer of 
the γ-phosphate group from adenosine triphosphate (ATP) onto substrates, while protein 
phosphatases remove phosphate groups from phospho-substrates with the aid of ordered 
water molecules (19,20). Since reversible phosphorylation is one of the strategies that cells 
use to respond to intracellular and extracellular stimuli and regulate almost all aspects of 
cellular life, abnormal protein phosphorylation leads to many human diseases, such as 
chronic inflammatory diseases, cancer, and diabetes (21).  
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Figure 1.2. Reversible protein phosphorylation is under the control of protein kinases 
and protein phosphatases resulting in protein conformational changes. Protein kinases 
are responsible for catalyzing the transfer of the γ-phosphate group from adenosine 
triphosphate (ATP) onto substrates, while protein phosphatases remove phosphate groups 
from phospho-substrates with the aid of ordered water molecules Modified from Zhang, 
(2003) (20).  
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1.2 Protein Phosphatase Superfamily 
Reversible phosphorylation is one of the key regulatory mechanisms in all living 
organisms, with 2% of the genome in most eukaryotes encoding protein kinases. It is 
reported that in the human genome there are 518 protein kinases, which consists of 90 
protein tyrosine kinases (PTKs) and 428 protein serine/threonine kinases (PSKs) (19,22). 
It was predicted that there should be a similar number of protein phosphatases based on the 
specificity of signaling pathways and the reversible nature of protein phosphorylation (23). 
The protein phosphatase superfamily is classified into two sub-families, which are 
the protein serine/threonine phosphatases (PSPs) and protein tyrosine phosphatases (PTPs).  
These two major sub-families are divergent based on their different phospho-substrates, 3-
D structures, and catalytic mechanisms (4,24,25). However, annotation of the human 
genome revealed only 137 members of the phosphatase superfamily, with 30 members 
classified as protein serine/threonine phosphatases (PSPs) and 107 protein tyrosine 
phosphatases (PTPs). This discrepancy in numbers between PSKs and PSPs is explained 
by the fact that there are fewer PSP catalytic domains, but hundreds of gene products that 
represent regulatory domains that collectively create comparable numbers of PSP 
holoenzymes for dephosphorylating phosophoserine/threonine specific substrates (23).  
Moreover, the PSPs superfamily contains three sub-families: phosphoprotein 
phosphatases (PPPs), the catalytic domain of which associate with a large number of 
regulatory subunits as mentioned above; metal-dependent protein phosphatases (PPMs), 
where catalytic activity requires metals such as manganese/magnesium (Mn2+/Mg2+); and 
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the aspartate-based phosphatases, in which an aspartate residue is necessary for catalytic 
activity (23). 
The other major class of phosphatases are the cysteine based family of PTPs. There 
are currently 107 annotated PTPs in the human genome, 105 of which have a mouse 
orthologue. The number of PTPs is more than anticipated since there are only 90 PTKs. 
However, only 96 of the PTPs are catalytically active, of which 2 dephosphorylate mRNA, 
and the substrates of 13 PTPs are inositol phospholipids, so therefore there are 81 active 
protein phosphatases, suggesting substrate specificity (26).   
As shown in Fig.1.3, the PTP superfamily is subdivided into four major families 
based on substrate specificity and architecture of the catalytic domain (26,27). Class I, 
which is the largest group in the PTP superfamily, are cysteine-based PTPs, and can be 
further divided into two subfamilies. First are the tyrosine-specific classical PTPs, which 
contain 21 receptor PTPs and 17 non-receptor PTPs, all of which have mouse orthologues. 
A second subfamily is VH1-like vaccinia virus gene H1 dual-specificity phosphatases 
(DSP subfamily) comprised of 61 members. This group is the most diverse, due to their 
substrates consisting of pTyr, pThr, and pSer residues, as well as mRNA, and inositol 
phospholipids. Class II also belongs to the cysteine-based PTP family, but only has low 
molecular weight PTP members. Class III, another cysteine-based PTP family, is 
comprised of three cell division cycle 25 (CDC 25) members. There are four Class IV 
aspartic acid-based PTP family members. Although the evolutions of class I, II and III are 
independent, they share a similar active site structure and catalytic mechanism (25-27).  
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Figure 1. 3. Classification and substrate specificity of protein tyrosine phosphatases. 
Protein tyrosine phosphatase superfamily can be divided in to four classes based on their 
substrate specificity and architecture of catalytic domain. Class I, II, III are Cysteine-based 
families, while Class IV is Aspartic acid-based family. Class I is the largest family and can 
be further divided into tyrosine-specific-Classical PTPs which contains receptor PTPs and 
non-receptor PTPs subclasses, and DSP subfamily. Modified from Alonso, et al. (2004) 
(28).  
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1.3 Catalytic Mechanism of Protein Tyrosine Phosphatases  
Despite PTPs having limited sequence identity, the catalytically active members 
share a signature motif (D...CH(X)5RS/T) in the catalytic domain and a common catalytic 
mechanism that is based on formation of a thiol-phosphate intermediate (25,28,29).   
The unique microenvironment of the active site cleft of PTPs decreases the pKa of 
the catalytic cysteine thiol (~4) which helps the cysteine (RS-) perform a nucleophilic 
attack on the electron-deficient phosphate group bound to the substrate, thus forming an 
enzyme-substrate complex. An aspartic acid residue located upstream of the active site 
donates a proton to release the dephosphorylated product (30-32). The same aspartic acid 
residue activates a water molecular in the next step to hydrolyze the phospho-enzyme 
intermediate to regenerate the enzyme (30-32). During the dephosphorylation process, the 
upstream aspartic acid now acts as a catalytic base (as opposed to its role as a catalytic acid 
in the first step). Arginine and serine residues are responsible for stabilization of the 
phosphate and thiolate ions respectively, and the ordered water molecule is coordinated by 
a invariant glutamine residue present around the active cleft (shown in Fig.1.4) (30-32). 
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Figure 1.4. Catalytic mechanism of protein tyrosine phosphatase. The first step of 
dephosphorylation catalyzed by protein tyrosine phosphatase is thiol-phosphate 
intermediate formation. The catalytic cysteine thiol performs a nucleophilic attack on the 
electron-deficient phosphate group bound to the substrate, thus forming an enzyme-
substrate complex. An aspartic acid residue located upstream of the active site donates a 
proton to release the dephosphorylated product. The second step is phosphatase 
regeneration, the same aspartic acid residue activates a water molecular to hydrolyze the 
phospho-enzyme intermediate to regenerate the enzyme During the dephosphorylation 
process, the upstream aspartic acid now acts as a catalytic base (as opposed to its role as a 
catalytic acid in the first step). Arginine and serine residues are responsible for stabilization 
of the phosphate and thiolate ions respectively, and the ordered water molecule is 
coordinated by a invariant glutamine residue present around the active cleft From Tanner, 
et al. (2011) (30).  
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As mentioned above, the substrates of PTPs are not only phosphorylated proteins 
but also inositol phospholipids and mRNA. The specificity of substrates is mainly 
determined by the depth of the active site cleft within PTPs.  The additional regulatory 
domains of many PTPs also contribute to substrate specificity. For instance, PTP1B, the 
first characterized PTP, dephosphorylates pTyr found on proteins since it has a deep active 
site cleft. The active site clefts of DUSPs are much shallower and can accommodate pTyr, 
pSer, and pThr residues. VHR has a shallow active pocket to allow hydrolysis of pSer, 
pThr, and pTyr residues, while the lipid phosphatase myotubularin-related protein 2 
(MTMR2) and phosphatase and tensin homologue (PTEN) possess broader active site 
clefts that allow the sugar head group of the inositol phospholipid to fit into their clefts 
(Fig.1.5) (31,33-37).    
Containing one or more modular domains is one of the most common features of 
PTPs. At least 79 PTP members have been reported having one or several additional 
regulatory or functional domains or motifs, most of which are responsible for protein-
protein, protein-lipid interactions, or subcellular localization (28). However, the functions 
of some regulatory domains are still poorly understood, such as the pleckstrin homology-
glucosyltransferases, Rab-like GTPase activators and myotubularins (PH-GRAM) domain 
which is located at the N-terminal of MTMR2, and the novel C-terminal zinc coordinating 
domain of the atypical DUSP human orthologues of the yeast VH1-like phosphatase 
(hYVH1 or DUSP12) (Fig.1.6) (28,34,38,39). 
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Figure 1.5. Comparison of the active site clefts of different protein tyrosine 
phosphatase members. PTP1B has a deeper active site cleft compared with VHR, 
MRMR2 and PTEN, VHR demonstrated to have a shallower catalytic pocket, while 
MRMR2 and PTEN have much shallower and broader clefts compared with PTP1B and 
VHR. From (A) Begley, et al. (2006) and (B) Lee, et al. (1999) (35,37). 
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Figure1. 6. Domain arrangement of all protein tyrosine phosphatases. Abbreviations 
are described as following: PTP, protein tyrosine phosphatase domain; coil, coiled-coil 
domain; GB, glycogen binding; mRC, mRNA capping; PBM, PDZ binding motif; pepN, 
N-terminal peptidaselike; PH-G, pleckstrin homology-“GRAM” domain; Pro-rich, 
proline-rich; Sec14, Sec14p homology (or CRAL/TRIO). In addition, a small black box 
signifies transmembrane stretch and a red cross over a PTP domain signifies catalytically 
inactive domain. From Alonso, et al. (2004) (28).  
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1.4 Redox regulation of protein tyrosine phosphatase 
The catalytic activity of PTPs is regulated at different levels, for example, their 
expression level, mRNA level, subcellular localization, and suite of post-translational 
modifications (4). Reversible phosphorylation under the regulation of phosphatases and 
kinases is one of the mechanisms that cells utilize to respond to intracellular and 
extracellular environmental changes. Recently, the catalytic activity of PTPs was found to 
be regulated by reversible oxidation (40-42).  PTPs are targets of reactive oxygen species 
(ROS) such as hydrogen peroxide (H2O2) ., superoxide (O2-)., oxidized glutathione 
(GSSG)., and reactive nitrogen species (RNS) including nitric oxide (NO), and S-
nitrosothiols (RSNO).  Much attention has been given to studying how PTP oxidation is 
involved in signaling pathway regulation (4,41,43,44). Specifically, when PTPs are 
oxidized the catalytic Cys residue is converted into an inactive form which cannot function 
as a nucleophile, leading to propagation of tyrosine phosphorylation-dependent signaling 
pathways. When the oxidation modification is reversible, PTP activity is restored upon 
return to reducing conditions, and the tyrosine phosphorylation-based signaling pathway 
can be attenuated (4,26,40,42).  
  The side chain of Cys residue demonstrates a diverse range of oxidation states that 
can be classified into two main types. One is reversible, including sulfenylation (SOH), 
disulfide bonds (RS-SR’), S-nitrosylation or S-nitrosation (SNO), sulfhydration (SSH), and 
glutathionylation (RS-SG). The second type is irreversible, and includes sulfinic acid 
(SO2H) and sulfonic acid (SO3H) (30,45). The unique microenvironment of the active site 
cleft of PTP family makes the catalytic Cys residue have a low pKa (4-6.5), thus the 
catalytic Cys residue is susceptible to oxidation, leading to PTP inactivation (41,46). 
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Although the Cys residue is usually reversibly oxidized, but not oxidized further than SOH, 
the oxidation states of catalytic Cys residues among PTP family are different. For example, 
the Cys sulfur atom of PTP1B forms a 5-atom cyclic sulphenamide with the main chain 
nitrogen of the adjacent Ser residue (44). CDC25, PTEN, and low MW PTPs demonstrate 
disulfide bonds to protect enzymes from irreversible inactivation due to a second Cys 
residue within the active site. The Vacratsis lab has shown that human YVH1 forms 
intramolecular disulfide bonds at both the catalytic domain and zinc binding domain (ZBD) 
with differential thiol-labeling and mass spectrometry techniques (47).  Finally, vaccinia 
H1 related (VHR) exhibits a distinct mechanism against irreversible oxidation, involving 
two VHR molecules forming a dimer to block the active site to reduce the chance of 
exposure to solvent, also decreasing VHR catalytic activity in this form (48). 
1.5 Dual-specificity tyrosine phosphatases (DSPs) subfamily  
   DSPs represent a large and heterogeneous group of protein phosphatases. The 
ability to dephosphorylate both pTyr and pSer/pThr containing substrates is the most 
unique feature of DSPs (27,28). It comprises 61 members and can be divided into seven 
subgroups based on the sequence similarity and the presence of specific regions. They are 
phosphatase and tensin homologue deleted on chromosome 10 (PTENs), slingshots 
(SSHs), myotubularin-related proteins (MTMRs), CDC14 phosphatases, phosphatase of 
regenerating liver (PRLs), mitogen-activated protein kinase phosphatases (MKPs), and 
atypical DSPs (As shown in Fig.1.3) (27,28). 
MKPs are the best-characterized DSP subgroup due to their ability to inactivate 
MAPK signaling pathways.  MKPs can recognize and dephosphorylate the pThr and pTyr 
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residues within the consensus sequence pThr-Xaa-pTyr of MAPKs simultaneously. 
Furthermore, the N-terminus of MKPs contains a CDC25-like domain (also termed CH2 
domain for CDC25 homology 2) which is responsible for substrate docking and specificity 
(4,28,49,50).   
The largest DSP subgroup is the atypical DSPs, containing 19 poorly characterized 
enzymes. Atypical DSPs were originally grouped into the MKP subfamily because they 
share common primary sequence characteristics.  However, further research has shown that 
many atypical DSPs lack the N-terminal cdc25-like domain and have different substrate 
specificities and physiological functions from MKPs (4,28,39).  
1.5.1 The dual specificity phosphatase YVH1 
The first eukaryotic dual specificity phosphatase, YVH1 (yeast VH1) was 
discovered in Saccharomyces cerevisiae by the Dixon group in 1992 (51). It is reported 
that YVH1 shares 25% identity with vaccinia virus VH1 phosphatase, and the amino acids 
for substrates binding and catalytic activity are conserved. YVH1 contains a N-terminal 
dual specificity phosphatase domain and a C-terminal zinc-binding domain (ZBD) (39,52-
54). Early work in yeast discovered that the mRNA level of YVH1 is dramatically 
increased by nitrogen starvation and low temperatures (51,55). Knockdown of  yvh1 gene 
expression leads to a slow growth phenotype compared to wild type yeast, as well as spore 
maturation deficiency, and a decrease in glycogen accumulation (51,55). 
Recent studies in yeast demonstrated that YVH1 is a novel 60S ribosome 
biogenesis factor and is necessary for the late stage of 60S subunit maturation (52,56,57). 
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Deletion of the yvh1 gene leads to the nuclear accumulation of pre-60S ribosome particles 
and the persistence of mRNA turnover protein 4 (Mrt4) remaining on the pre-60S particle. 
Mrt4 is an inhibitor of ribosome stalk docking, and needs to be exchanged from the 
maturing 60S subunit in order for the ribosome stalk to associate and complete 
translationally active ribosome maturation on pre-60S subunits in the cytoplasm. This 
suggests that YVH1 is involved in the export of pre-60S particles from the nucleus to 
cytoplasm and is essential for ribosome maturation (52,56). The ZBD, but not the catalytic 
domain, is essential for 60S ribosome subunit localization, which was shown by domain 
deletion experiments (Fig.1.7) (52,56).   
YVH1 only co-enriches with late pre-60S particles and not with early pre-
ribosomes or the final mature 80S translating ribosome (52,56). Moreover, deletion of ZBD 
attenuates its association with 60S ribosome subunits.  This suggests that the ZBD is 
essential for YVH1 interacting with 60S ribosome, while the catalytic domain has an 
unknown role for the ribosome biogenesis function of YVH1 (52). 
1.5.2 The dual specificity phosphatase hYVH1 (DUSP12) 
Human orthologue of YVH1 phosphatase (hYVH1, also termed as DUSP12) was 
first cloned in 1999 (39). The hyvh1 gene is located on chromosome 1q21-q22, which 
encodes a ubiquitously expressed protein that contains 340 amino acids (39). The domain 
arrangement of hYVH1 is similar to YVH1; it consists of an N-terminal catalytic domain 
that is essential for phosphatase activity and a C-terminal zinc binding domain which 
coordinates 2 moles of zinc per mole of protein (Fig.1.8) (39). hYVH1 shares 31% 
sequence identity with YVH1 and can rescue the deficiency of yeast induced by YVH1 
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knockdown (39). Moreover, catalytic inactivation of hYVH1, but not ZBD deletion variant, 
was still able to restore normal growth of yeast that was induced by lack of YVH1. This 
indicates that the C-terminal ZBD is required for YVH1 function in vivo (39). 
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Figure 1. 7. The mechanism of YVH1 in 60S ribosome subunit maturation (A and B) 
and Zinc binding domain of YVH1 is essential for ribosome interaction (C). A, Mrt4 
is replaced byYvh1 which is then released by P0 to construct the ribosome stalk. In turn, 
the ribosome stalk associates and actives ribosome maturation on pre-60S subunits in the 
cytoplasm. (B) Cartoon showing the events depicted in (A). C, Samples were centrifuged 
to separate free protein and ribosome particles. Equal amounts of supernatant (S) and pellet 
(P) fractions were separated by SDS-PAGE, immunoblots were performed with antibodies. 
(A, B) from Lo, et al. (2010) and (C) from Lo, et al. (2009) (52,57). 
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Figure 1.8. Domain arrangement of the atypical dual specificity phosphatase, hYVH1. 
HYVH1 contains N-terminal catalytic domain and C-terminal Zinc binding domain. The 
catalytic domain contains the highly conserved HCX5R(S/T) motif along with three 
additional Cys residues. The zinc binding domain coordinates two moles of zinc possesses 
seven Cys residues.   
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Recently, studies identified that heat-shock protein 70 (Hsp70) as a novel hYVH1-
binding partner. The C-terminal ZBD is required for Hsp70-hYVH1 interaction, 
determined through a mass spectrometry-based method and immunoprecipitation (58). 
Overexpression of hYVH1 can protect cells from cellular stresses, for example, heat shock-
, H2O2-, and Fas receptor activation, each of which induce cell death through redox-
sensitive signaling pathways, while it cannot repress cell death from the DNA-damaging 
agents such as cisplatin (58). In addition, co-expression of hYVH1 with Hsp70 
synergistically enhanced cytoprotection and hYVH1 co-localized with Hsp70 to the 
perinuclear region under heat stress in HeLa cells, suggesting that hYVH1 is a novel cell 
survival phosphatase that protects cells from different cellular stress conditions (58). 
Furthermore, deletion of the ZBD or expression of catalytically inactive hYVH1 failed to 
rescue cells from cellular insults, indicating that both phosphatase activity and the ZBD of 
hYVH1 are indispensable for the effects of hYVH1 on cell viability (58). 
hYVH1 expression was also shown to be a modulator of cellular DNA content (59). 
Specifically, ectopic overexpression of hYVH1 in HEK293 cells significantly increases the 
G2/M and polyploidy cell population, corresponding to the cell population of G0/G1 
decreasing (59). Moreover, the ZBD of hYVH1 is necessary and sufficient for hYVH1-
mediated cell cycle changes, for which N-terminal catalytic domain of hYVH1 is not 
necessary. This further confirmed previous findings that ZBD of hYVH1 is very important 
for its functions in vivo (59). The drastic increase of G0/G1 cell population and 
susceptibility to cellular senescence was observed in human embryonic kidney cells 
(HEK293) in which hYVH1 expression level is down regulated with siRNA (59).  
21 
 
Mass spectrometry-based phosphorylation studies showed that the cellular 
localization of hYVH1 is affected by Ser335 phosphorylation status. It was also observed 
that phosphorylated Ser335 augments the hYVH1 G2/M phenotype. Moreover, Ser335 is 
located in the zinc binding domain of hYVH1. These findings suggest that the C-terminal 
zinc binding domain plays a key role in hYVH1’s physiological functions (59).  
The roles of hYVH1 in 60S ribosome biogenesis, cell cycle, and cell survival 
mentioned above have led to the hypothesis that hYVH1 may support tumor cell growth 
and survival (56,58,59). Moreover, the location of hYVH1 gene on chromosome 1q21-q22 
is a region often amplified in many neoplasms. In addition, previous studies showed 
amplification of the hyvh1 gene in multiple soft tissue sarcomas, and pediatric 
ependymomas (60).  hYVH1 protein was also found highly overexpressed in CD34+ 
progenitor cells from chronic myelogenous leukemia patients. Polymorphisms within and 
surrounding the hyvh1 gene are associated with Type-2 diabetes (61-65). All of these 
findings suggest that hYVH1 plays an important role in fundamental cellular processes, 
but requires further investigation to elucidate mechanistic insight into its exact role in 
cellular regulation.  
1.6 Ribosome biogenesis 
Ribosomes are the fundamental macromolecular factories that responsible for converting 
the information encoded within mRNA to protein, playing a pivotal role in cell life (66).  The 
eukaryotic 80S ribosome is an example of ribonucleoprotein (RNP) particles, it consists of two 
ribosomal subunits, a large subunit (60S) and a small subunit (40S), both of which contains 
ribosomal RNAs (rRNAs) and numerous ribosomal proteins (r-proteins) (67,68).   
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Ribosome biogenesis is a highly complicated and most demanding energetic process in 
cells, and more than 170 factors are reported to be involved in the process of ribosome biogenesis 
so far (66-69).  In general, ribosome biogenesis begins with the transcription of 28S, 5.8S and 18S 
rRNAs as a single precursor transcript in nucleolus, while 5S rRNA is transported to nucleolus 
from nucleus in where 5S rRNA transcription takes place (68).  Once transcribed, rRNAs undergo 
modification, cleavage, fold and association with ribosomal proteins (70).  90S particle is the 
earliest reported pre-ribosome complex that contains 35S/47S precursor rRNAs, numerous 
ribosomal proteins and non-ribosomal proteins(71). The cleavage of precursor rRNAs within 90S 
pre-ribosome enable to separate the maturation pathways of two ribosomal subunit by yielding pre-
40S and pre-60S ribosome particles (66,67,72).  Pre-ribosomal subunits have to be exported to the 
cytoplasm for maturation, pre-40S subunit can be transported immediately to cytoplasm, while pre-
60S particle undergoes nuclear maturation before late stage of cytoplasmic maturation (66). 
1.7 Stress granule assembly   
Stress granules (SGs) are highly dynamic, non-membranous cytoplasmic foci formed when 
cells are under cellular stresses, including heat, oxidative, starvation and viral infection; they are 
composed of non-translating mRNA, various translation initiation factors and many other proteins 
affecting mRNA function (73-77).  The formation of SGs is one of the major cellular defence 
mechanisms by suppressing mRNA translation, while energy goes to the expression of heatshock 
proteins that protect cells from stresses (78). The dynamics of SGs are found to be related to 
diseases, its formation in some cancer cells potentially assist cancer cells survival (78). SG 
demonstrates a dynamic shell-like structure surrounding stable core; the assemble, disassemble and 
transition between the core and shell are regulated by numerous proteins (74,78). 
Classically, stress induces phosphorylation of the translation initiation factor 2 (eIF2a) to 
prevent mRNA translation initiation and form 43S pre-initiation complexes (79). Proteins that have 
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self-aggregation property, such as, T-cell intracellular antigen-1 (TIA1) or the Ras-GAP SH3 
domain-binding protein (G3BP) binds to the mRNAs within 43S complexes, leading to the 
formation of stalled 48S pre-initiation complexes (79-81). Then, self-aggregation of TIA1 or G3BP 
results in the accumulation of these 48S complexes to form SGs until heat shock proteins reverse 
this process or stresses are removed and protein synthesis is resumed (78,79).  
1.8 Mass spectrometry  
Mass spectrometry (MS) is one of the most widely used analytical techniques for 
both quantitative and qualitative applications. Since Tanaka and Hillenkamp et al., 
developed matrix-assisted laser desorption/ ionization (MALDI) and Fenn et al. 
demonstrated the possibility of obtaining proteins’ mass spectra with electrospray 
ionization (ESI) in the late 1980s, mass spectrometry has been widely used in proteomic 
studies to analyze post-translational modifications, protein quantification, protein 
structural information, and protein identification (82-86). In brief, MS sorts and analyzes 
chemical species based on their mass to charge ratio (m/z) in electronic and/ or magnetic 
fields. The main components of a mass spectrometer are the ionization source, mass 
analyzer, detector, data processor, and vacuum pumps (Fig.1.9) (83).     
1.8.1 Ionization source   
To perform MS, the analyte must first be ionized before being introduced into the 
mass spectrometer. MALDI and ESI are two common ionization methods for biological 
MS (83,87). MALDI and ESI are capable of desorbing large biomolecules into the gas 
phase without affecting their integrity. They are both less harsh on the sample than other 
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ionization sources, but achieve the same outcome, and thus are named “soft” ionization 
techniques (83). 
MALDI utilizes a matrix compound which is able to absorb ultraviolet (UV) light.  
2,5-Dihydroxy benzoic acid (DHB), 4-Hydroxy-alpha-cyanocinnamic acid, and Sinapinic 
acid are the most typical matrix compounds for peptide analysis (83,88). Analyte is mixed 
with UV absorbing matrix in a volatile solvent to form co-crystals. When the UV laser hits 
the crystals, the matrix will absorb energy and carry intact analyte molecules to the gas 
phase (Fig.1.10A). During this process, protons are transferred between matrix and analyte 
leading to positively or negatively charged analyte molecule formation (83,85,89).   
ESI relies on the utilization of high voltage and heat for desolvating peptide 
molecules. Samples are usually fractionated by reverse phase high performance liquid 
chromatography (HPLC) to decrease sample complexity. Liquid sample flows through a 
narrow capillary that is electronically charged, while the high voltage applied to the 
capillary pulls liquid sample out of capillary and forms small drops. This causes the solvent 
in the droplets to quickly evaporate; the number of charges on the surface of droplets 
increase until they explode to smaller drops (Fig.1.10B). This process is repeated several 
times until they are kinetically and energetically ready to be injected into the mass analyzer 
(83,84). 
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Figure 1.9. Components of a mass spectrometer. A mass spectrometer consists of sample 
introduction device, ion source for ion generation, m/z analyzer for ion separation and ion 
detector to transform analogue signals into digital signals and record a mass spectrum. 
Modified from Canas, et al. (2006) (83). 
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Figure 1.10. The schematic of ion formation from A) Matrix assisted laser desorption 
ionization (MALDI) source. Analyte is mixed with UV absorbing matrix in a volatile 
solvent to form co-crystals. When the UV laser hits the crystals, the matrix will absorb 
energy and carry intact analyte molecules to the gas.  B) electrospray ionization source 
(ESI). The analyte flows through a charged capillary, resulting in the creation of charged 
droplets that evaporate with the aid of a stream of nitrogen. The solvent in droplets quickly 
evaporate; the number of charges on the surface of droplets increase until they explode to 
smaller drops and eventually is completely evaporated as speculated based on the charge 
residue theory. Modified from El-Aneed et al. (2009) (87).  
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1.8.2 Mass analyzer 
Ionized analyte in the gas phase is separated in the mass analyzer. After leaving the 
ionization source, either electric or magnetic fields can be applied for their separation. 
Three commonly used mass analyzers in proteomics applications are time-of-flight (TOF), 
quadrupole, and ion traps (83). TOF is the simplest analyzer, and typically uses MALDI as 
its ionization source. The main principle of TOF is that ions with equal energies accelerate 
in a strong electrical field (high vacuum flight tube) (Fig.1.11A). The length of flight tube 
is the same for all ions, so the velocities of ions are inversely proportional to their masses 
as shown in equation (1). Ions are separated because of their different velocities, as lighter 
ions arrive at the detector earlier than heavier ions (90,91). 
KE=1/2(mv2)                             (1) 
KE is kinetic energy, m is the mass of ion, v is the velocity of ion. 
In theory, there is no upper limitation of m/z values in TOF-MS, while the 
resolution of TOF-MS is relatively low. However, the resolution can be improved by using 
an electrostatic mirror called a reflectron. This is referred to as a reflectron TOF analyzer. 
One consequence of this analyzer is a decrease in sensitivity (83,90). 
The quadrupole mass analyzer consists of four electrically hyperbolic or cylindrical 
parallel rods which are linked to two voltages, direct current (DC) and radio frequency 
(RF), or alternate current (AC), to create the electrical fields to separate ions. Contiguous 
rods have opposite DC polarity, while the AC forms an electrically oscillating field. 
Therefore, only ions with stable trajectories will travel through the quadrupole mass 
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analyzer and reach the detector, while ions with unstable trajectories will not reach the 
detector because of collision with electrical rods (Fig.1.11B). Compared with TOF, the 
mass range of quadrupoles is limited, usually the limit of m/z ratio is 4000, below this level 
the sensitivity will decrease. Nevertheless, quadrupole is a very powerful mass analyzer in 
biological applications due to their fast scanning speed and ease of tuning for targeted 
approaches (83,92).  
Ion traps were not commercialized until 1996 although developed in the 1950s. 
Along with quadrupoles and TOFs, they are one of the most common mass spectrometers 
applied in proteomics. As the name implies, ions are retained inside a quadrupole trap and 
can remain trapped during the time needed to perform further analysis, such as, full scan, 
precursor selection, fragmentation, and product ion analysis (Fig.1.11C). The time of ions 
entrapped lasts from seconds to hours. Moreover, the process of ion selection, 
fragmentation, and decomposition can be repeated several times which is known as MSn. 
Ion trap mass analyzers can produce data quickly, and have high sensitivity for detecting 
peptides when combined with a nanospray source (83,93,94). 
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Figure 1. 11. Mass analyzer, A) Time of flight (TOF), B) Quadrupole, C) Ion trap. 
Modified from Glish, et al. (2003) (95). 
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Tandem mass spectrometry (also known as MS/MS or MS2) is widely used in 
proteomics studies, which involves multiple steps of ion selections and fragmentation. It is 
most commonly performed using a triple quadrupole arrangement (96). Specifically, ions 
are formed in ion sources, and separated in the first stage of the mass analyzer according 
to the different m/z ratios. Ions with a particular m/z value (precursor ions) are selected and 
induced to fragment through collision-induced dissociation, or other fragmentation 
methods in the second quadrupole (or collision cell). Ions or fragments are separated and 
detected in the third quadrupole (or the second mass analyzer) as shown in Fig.1.12 (97-
99).  
In recent years, MS has been used to examine structural insights when combined 
with hydrogen-deuterium exchange (HDX) labeling of proteins.  HDX studies of proteins 
date back to Linderstrøm-Lang’s work in the 1950s where he examined H-bonded 
structures in proteins (100). Traditionally, HDX methodology was used in combination 
with nuclear magnetic resonance (NMR) analysis.  HDX-MS is a more recent 
development; the first application of MS as a detector for HDX rates came shortly after 
ESI development in the 1990s (101,102). Since then HDX-MS has been applied to study 
protein structure, protein dynamics, protein-ligand interactions and protein-protein 
interactions (101,103-109). Hydrogen atoms within a protein are labile, exchanging with 
hydrogens existing in the surrounding solvent all the time, although this conversion is not 
detectable by MS (110). HDX-MS relies on amide hydrogens (—C(O)—NH—) on a 
protein backbone to exchange with deuterium when the protein is exposed to a D2O-
containing solvent. The ~1 Da difference resulting from exchange of a hydrogen to 
deuterium can be detected by MS, and each exchange that occurs can be measured as such. 
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Usually the rates of exchange depend on the positions of amino acids as each amino acid 
(except proline) has a backbone amide hydrogen participating in different structures (i.e.α-
helix, β-sheet or loop) and therefore have different HDX rates. Specifically, amino acids 
exposed to solvent have faster deuterium exchange rates than those buried in the protein’s 
interior since the latter are more protected from deuterium exchange (107). Therefore, the 
rates of exchange for amide hydrogens provide information about solvent accessibility of 
amide hydrogens, offering insight on structural topology and conformational dynamics 
(107). 
In HDX-MS, proteins are exposed to D2O containing buffer for various amounts of 
time; then the hydrogen/deuterium exchange is then quenched at low pH, and analyzed by 
MS.  Numerous factors such as solution pH, temperature, side chain effects (steric effects), 
as well as hydrogen-bonding network, influence exchange rate (111). Low pH and low 
temperatures are critical to reduce back exchange of deuterium for hydrogens during 
subsequent HDX-MS.  Therefore, HDX-MS is usually performed at pH ~2.5 and all the 
steps including chromatography are performed at 0 °C. The side chains of both the amino 
acid and its adjacent amino acids affect the exchange rate by inductive effect and steric 
effect; these two effects are additive and can change exchange rate by a factor of 10 
(100,111-114). If the hydrogen is involved in hydrogen-bonding or buried in the proteins 
interior, the exchange rate is slower than those hydrogens in unstructured proteins where 
amino acids are more exposed and more suitable for exchange.  To achieve higher spatial 
resolution, proteins are usually subjected to rapid proteolysis (e.g. pepsin) at low pH before 
injection into the mass spectrometer for analysis. HDX-MS structural information at the 
amino acid level is aided by analyzing multiple overlapping peptides (113,115). 
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Figure1. 12. Tandem mass spectrometer (Triple Quadrupole) Mass Analyzer. Ions 
are formed in ion sources, and separated in the first stage of the mass analyzer according 
to the different m/z ratios. Ions with a particular m/z value (precursor ions) are selected 
and induced to fragment through collision-induced dissociation, or other fragmentation 
methods in the second quadrupole (or collision cell). Ions or fragments are separated and 
detected in the third quadrupole (or the second mass analyzer). Modified from Paulo, et 
al. (2012). (116).  
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1.9 Objectives 
Although YVH1 orthologues were discovered over twenty years ago, there is 
limited knowledge regarding the structural and biological properties of this conserved 
phosphatase.  Therefore, the objectives of this dissertation are to deepen our understanding 
of the regulatory and structural properties of hYVH1 using mass spectrometry, combined 
with biochemistry and cell biology techniques. 
Specifically, we aim to: 
1. Develop novel thiol-labeling and enrichment strategies to investigate the redox-
regulation of protein tyrosine phosphatases, with emphasis on hYVH1, using mass 
spectrometry. 
2. Identify and functionally characterize novel hYVH1 complexes using affinity 
chromatography and mass spectrometry. 
3. Examinine structural properties of the atypical dual specificity phosphatase 
YVH1 using hydrogen/deuterium mass spectrometry. 
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CHAPTER 2 
Investigating Redox Regulation of Protein Tyrosine Phosphatases Using Low pH 
Thiol Labeling and Enrichment Strategies Coupled to MALDI-TOF Mass 
Spectrometry 
2.1 Introduction 
Cells utilize a vast array of strategic phosphorylation events to properly respond to 
extracellular stimuli.  To achieve this homeostatic phosphorylation, kinases and 
phosphatases must therefore be tightly controlled using a variety of temporal and spatial 
regulatory mechanisms.  Although often considered the unfavorable by-products of aerobic 
respiration, increasing evidence has highlighted the role of cellular oxidants as second 
messenger molecules which participate in maintenance of this balanced phosphorylation 
(1). Disruption of this delicate equilibrium can cause or promote numerous human disease 
states including cancer, diabetes, and neurodegenerative disorders (2-4). 
Reactive oxygen and nitrogen species (ROS/RNS) have been shown to target 
multiple members of the protein tyrosine phosphatase (PTP) superfamily, providing a tier 
of transient and reversible post-translational regulatory control (5). PTPs share a highly 
conserved active site architecture and catalytic mechanism, in which their catalytic 
activities depend on nucleophilic cysteine thiolates (-S-) (6,7). Moreover, PTPs possess an 
invariant signature motif, HCX5R(S/T), responsible for the thiolate-based 
dephosphorylation of an ever increasing diversity of phosphorylated substrates (8-11). This 
tertiary architecture and microenvironment reduces the pKa of the catalytic thiol to enhance 
catalytic competency, but also renders these enzymes susceptible to reversible oxidative 
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inactivation (12-15). As such, these enzymes pose as molecular ‘redox switches or sensors’ 
and can be regulated by discrete, subtle and/or sudden changes in cellular redox 
homeostasis (16). 
The prevalence, type(s) and effects of oxidative modifications among PTP family 
members continues to diversify; a likely consequence of slight variations in active site 
conformations or mediation through unique regulatory domains (14,17). Sulfenic acid, 
cyclic sulfenamide, nitrosylation, glutathionylation, sulfhydration and disulfide bond 
formation have all been shown to facilitate stable, reversible, active site modifications 
among various PTP family members (13,18-22). Thus, it was first suggested that oxidation 
predominantly and rapidly targets the active site cysteine resulting in inactivation, while 
other cysteinyl residues remain in the reduced state.  More recently, however, accumulating 
evidence is beginning to redefine redox regulation of PTPs as a far more dynamic 
modification capable of differential regulation. In some cases, redox sensitive cysteine 
residues outside of the active site contribute to preserving, or are even a necessity for, 
catalytic activity under oxidative conditions (23-25). 
Tools for studying PTP redox modifications are continually being developed, 
allowing for extraction of pertinent information regarding these regulatory post-
translational modifications (26). Recently, oxidative modification and conformation 
sensing antibodies have been developed as unique tools for studying individual PTP redox 
events at both the protein and/or proteomic level (27-30). However, the economics and 
feasibility of such applications requires targeted and previously determined phenotypes 
which limits their use in more practical applications such as preliminary screening. Some 
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of the more routine methods for examining protein thiol redox status rely heavily on 
differential labeling, whereby reversibly oxidized protein or peptide thiols are labeled with 
some 'reporter tag(s)' for subsequent identification using a variety of analytical techniques 
(31). Efforts from our laboratory have focused mainly on development of novel labeling 
and enrichment strategies allowing for quantitative and/or qualitative identification of 
protein thiol redox status using mass spectrometry (MS) (23,32,33). However, as in these 
and nearly all labeling methods, labeling steps must proceed for several hours at near 
neutral pH, in large molar excesses to ensure optimal and complete reactivity of thiolates 
for the specific labeling agents. It is under these conditions that targeted thiolates are also 
prone to non-specific oxidation events including those catalyzed by common buffer 
contaminants such as molecular oxidation and trace metals (i.e. disulfide bonds, sulfonates, 
etc.) which hampers their accurate analysis and interpretation (31). This issue can be partly 
circumvented by purging or degassing solutions used in sample handling, and performing 
cellular lysis under anaerobic conditions as those described by Meng et al. (34,35). These 
precautions are effective in limiting oxidation by ROS/RNS, but have decreased abilities 
in preventing disulfide exchange reactions as those commonly observed among members 
of the dual specificity phosphatase (DUSP) sub-families (19). Thus, accurate analysis of 
thiol oxidation, both in vivo and in vitro, balances between the ability to suppress non-
specific thiol exchange/oxidation and the specificity and reaction rate of labeling reagents 
used for modification, enrichment and detection. 
Recently, our laboratory has been characterizing the activities of human YVH1 
(hYVH1, also known as DUSP12), an atypical dual specificity phosphatase (DUSP) 
member of the PTP superfamily (8). This unique enzyme possesses an N-terminal DUSP 
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catalytic domain along with a C-terminal, thiol-rich, zinc binding domain (ZBD) which has 
been shown to be indispensable for its biological activities (Fig.2.1) (36). Notably, YVH1 
orthologues exhibit high evolutionary conservation, similar domain organization, and have 
recently been implicated in processes such as ribosome biogenesis and cell cycle regulation 
(36-39). Moreover, we previously revealed that oxidation of hYVH1 results in reversible, 
concomitant, enzymatic inactivation and zinc release in vitro through formation of 
intramolecular disulfide bonds. This inactivation is more pronounced in the absence of the 
ZBD, however, reversibility is independent of ZBD presence suggesting that oxidation 
preferentially targets this intrinsic redox buffering region, slowing the rate of oxidative 
inactivation (23). We have since observed that similar to the yeast orthologue, hYVH1 
interacts with the mammalian pre-60S ribosomal subunit, but, interestingly, oxidation 
ablates this association in a dose-dependent manner. Although no bona fide physiological 
substrate or function have been elucidated, amplification of the dusp12/hyvh1 gene has 
been reported in multiple sarcomas, implicating roles of hYVH1 among human 
pathophysiology, thus highlighting the need of further study (40-42).   
We have begun to develop rapid, specific, sensitive, and reversible low pH thiol 
labeling schemes for screening PTP oxidative modification, specifically those involving, 
but not limited to, disulfide exchange reactions as observed by Chen et al. for SHP-1 and 
SHP-2 (19). From our previous studies on the redox regulation of hYVH1, we have 
employed novel labeling and enrichment strategies in combination with mass spectrometry 
to develop a platform of simple, rapid and diverse labeling approaches for studying 
disulfide exchange reactions. Our data suggest that exchange reactions occur quite readily 
among vicinal thiols within the catalytic domain of this DUSP similar to results shown by 
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Chen et al. (19). We find that the active site cysteine is capable of participating in multiple 
disulfide bond reactions in addition to those previously described, to further provide 
protection against irreversible oxidation events. Moreover, we have found evidence of 
other disulfide pairs, exhibiting the applicability of the methodology to identifying 
reversible thiol oxidation. Ultimately, these methods serve to provide an economical means 
for preliminary screening of targeted redox-active thiols within PTP superfamily members, 
to in turn, warrant an in depth analysis under more detailed physiological settings. 
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Figure 2.1. Human YVH1 (DUSP12) is a thiol rich dual specificity phosphatase. 
Schematic displaying domain arrangement of hYVH1.The N-terminal phosphatase 
domain contains the highly conserved HCX5R(S/T) motif along with three additional Cys 
residues. The C-terminal zinc binding domain coordinates two moles of zinc possesses 
severn Cys residues. 
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2.2 Materials and Methods 
2.2.1 Site-directed mutagenesis, recombinant protein purification  
Target cysteine residues are identified through structural bioinformatics and/or 
redox active thiol enrichment (below), and mutated to serine residues using PCR-based 
site-directed mutagenesis. Mutated constructs are purified by conventional means in a 
suitable host organism and characterized by mass spectrometry. Site-directed mutagenesis 
was performed to generate pGEX-4T1 hYVH1 C115S constructs following manufacturers 
protocol (Stratagene), pGEX-4T1 ΔCT1 hYVH1 was synthesized as previously described 
(23,36,38). All mutated plasmid DNA constructs were confirmed by DNA sequencing 
(AGCT Corp.).  
Bacterial expression of pGEX/hYVH1 constructs and recombinant proteins were 
purified as previously described (36,38). Specifically, protein being eluted with 50 mM 
Tris-HCl, 150 mM NaCl, 2.5 mM CaCl2, 0.1 % 2-mercaptoethanol, 80 U thrombin (Sigma-
Aldrich) pH 8, at 4°C from glutathione-agarose (Sigma-Aldrich) to remove the glutathione-
S-transferase tag (23). Target constructs were brought to 1 mM dithiothreitol (DTT, Sigma-
Aldrich), 5% glycerol (ACP Chemicals Inc.) and 0.5 mM phenylmethylsulfonylfluoride 
(PMSF, MP Biomedicals), 0.2 µm sterile filtered, aliquoted at 130 µL and stored at -80 °C 
until use. All protein concentrations were determined against standard Bovine serum 
albumin (BSA, Sigma-Aldrich) as per Bradford assay, while purity of all proteins in this 
study was approximately 80–90% as judged by SDS-PAGE analysis.   
2.2.2 Characterization of protein constructs and digestion conditions 
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To characterize individual constructs along with digestion conditions at the protein 
level, each construct (~ 20 µg) was labeled with 25 mM iodoacetamide (IAM; stock 
solution in water, Sigma-Aldrich) for 60 min, shaking, at room temperature in the dark. 
Both labeled and unlabeled samples of each construct were next exchanged out of 
reducing/labeling conditions by precipitation, on ice, with cold (-20 °C) trichloroacetic acid 
(TCA, Sigma-Aldrich) at a final concentration of 15 %. Pellets were collected after 30 - 60 
min by centrifugation at 23 500 x g at 0 - 4 °C, washed 3 times with cold (-20 °C) acetone, 
then resuspended in 50 mM ammonium bicarbonate for subsequent proteolytic digestion. 
To each sample, trypsin was added to a final protease: protein ratio of 1:25, with digestion 
proceeding for 16 h, shaking at 37 °C. Digestions were quenched by addition of formic 
acid (FA, Sigma-Aldrich) to a final concentration of 0.1 %. Iodoacetamide labeled and 
unlabeled samples were combined, mixed, then split into equal volumes, where one was 
reduced with tris(2-carboxyethyl) phosphine (TCEP; stock solution in water, Thermo 
Scientific/ Pierce Biotechnology) shaking at room temperature for 15 min at a final 
concentration of 25 mM. Samples were spotted 1:1 with α-cyano-4-hydroxycinnamic acid 
(CHCA, Thermo Scientific/ Pierce Biotechnology) matrix constituted in 65 % 
acetonitrile/0.1 % trifluoroacetic acid by the dried-droplet method and analyzed by matrix 
assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). 
Remaining peptide samples were diluted to approximately 5 ng/µL in binding buffer (200 
mM phosphate buffer pH 4) for subsequent loading onto Hg-IMAC resin described below. 
2.2.3 Preparation of Mercury-Immobilized Metal Affinity Chromatography (Hg-IMAC) 
resin 
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The outlined procedures are primarily based on those for BioRad’s Affi-Gel- 501, 
an organomercurial derivative of Affi-Gel-10 N-hydroxysuccinimide activated agarose gel 
which has been discontinued, thus labs have compensated by preparing the resin in house 
(43-45).  
The following protocol is for preparation of approximately 4 mL of Hg-IMAC 
resin. Before use, the chemical compatibility of all plastics and vessels with the chemicals 
used throughout this synthesis should be determined. Also, we strongly advise strict 
adherence to Good Laboratory Practice (GLP) procedures and consultation of appropriate 
Material Safety Data Sheets (MSDS) during and before synthesizing Hg-IMAC resin. Prior 
to opening, Affi-Gel-10 resin (BioRad Laboratories, Inc) is warmed to room temperature 
for ~ 30 min in the dark to limit hygroscopy, which promotes hydrolysis of the activated 
succinimidyl ester. Dissolve 83.76 mg (240 µmol) of para-amino-phenylmercuric acetate 
(Sigma Aldrich) in 1.2 mL of anhydrous dimethylformamide (200 mM). Mix via vortex 
and/or nutation for 20-30 min at room temperature to ensure full dissolution of all 
organomercurial compound. Agitate Affi-Gel-10 resin to form a homogeneous suspension, 
then quickly transfer 4 mL into a clean 10 mL glass column with granulated frit, pre-rinsed 
with anhydrous dimethylformamide/2-propanol. It is imperative to eliminate residual 
water, as water promotes rapid hydrolysis of succinimidyl esters to decrease labeling 
efficiency of subsequent steps, and thus, binding capacity of Hg-IMAC resin.  
Wash resin with a minimum of 3 column volumes (12 mL) of anhydrous 2-
propanol, then resuspend resin in 1 column volume of anhydrous 2-propanol, ensuring not 
to let resin dry.  If resin dries and cracks, wash extensively with 2-propanol with periodic 
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aspiration to remove trapped air.  If the resin has begun to aggregate, restart the synthesis. 
Add the para-amino-phenylmercuric acetate solution to the resin (60 μmol/mL of gel) and 
aspirate carefully as to not introduce air bubbles into the resin.  Cover the column with tin 
foil and incubate for 4 h with periodic aspiration to mix the resin.  This constitutes a 
fourfold excess of organomercurial amine to available succinimide esters of the resin. Add 
40 µL of ethanolamine to block any unreacted succinimide esters (640 μmol/mL of gel), 
aspirate and incubate as above for 1 h. Control resin is prepared with the exclusion of para-
amino-phenylmercuric-acetate by simply blocking with excess ethanolamine. 
Wash resin with 3 column volumes (12 mL) of dimethylformamide, followed by 
12 column volumes (48 mL) of 2-propanol.  Store the resin in 2 column volumes (8 mL, 
approx. 30% slurry) of 2-propanol in the dark at 4°C.  If require or prefer higher percentage 
slurry, centrifuge resin at 2500 x g for 5 - 10 min or allow to settle at 4°C and remove the 
desired volume of 2-propanol. The resin should be within1 month in the dark at 4 ˚C, 
however, the quantity of resin prepared depends on the number of anticipated samples to 
be run over the experimental time frame. In our experience, resin maintained binding 
capabilities over 2 + months, however it is recommended that binding capacity is checked 
periodically to ensure reproducibility and efficacy. 
2.2.4 Characterization of Hg-IMAC binding capacity 
Prepare 1 mg/mL (5.7 mM) stock standard solution of cysteine hydrochloride (Cys-
HCl, Sigma-Aldrich) in water. Dilute ten-fold in water (final concentration is 570 µM) for 
use in binding capacity and standard curve analysis. Prepare stock 2 mM solution of DTNB 
(Sigma-Aldrich) in 50 mM sodium acetate pH 4.5.  A 12 point linear standard curve is 
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prepared by mixing Cys-HCl to final concentrations ranging from 5.7 µM to 114 µM with 
DTNB at a final concentration of 200 µM in 100 mM phosphate buffer pH 7.4 (Thermo 
Scientific, 1 mL final reaction volume) and recording the Abs412nm as per Riddles et al (46).   
Equilibrate and activate various amounts of Hg-IMAC resin slurry (0, 10, 20, 30, 
40, 60, 80 µL; see below for equilibration/activation steps) and incubate with 570 µM of 
Cys-HCl, mixing by rotation for 45 min.  For comparison, perform similar steps using the 
control resin. Collect resin by centrifugation at 4000 x g for 6 min, then mix 100 µL of 
each supernatant with DTNB at a final concentration of 200 µM in 100 mM phosphate 
buffer pH 7.4 (1 mL final reaction volume) and record the Abs412nm as per Riddles et al 
(46). 
Calculate the remaining thiol content and convert to μmol/mL of slurry. In our 
experience, the binding capacity of Hg-IMAC resin is reproducibly around 2.3 +/- 0.2 
μmol/mL of slurry (suppl. Fig. S2.1) when performed in a 1:1 phosphate buffered saline 
(PBS): water buffer pH 3.5 (adjusted with phosphoric acid) supplemented with a final 
concentration of 10 % acetonitrile, and is consistent with other values in the literature (47). 
Also, binding capacity studies have been performed over a range of pH's, buffers, and 
solvents, showing no significant deviations from the reported value above.   
2.2.5 Selective enrichment of cysteine containing peptides using Hg-IMAC resin 
Transfer Hg-IMAC resin slurry (at 100 µL/reaction) to a 1.5 mL conical 
microcentrifuge tube, harvest by centrifugation at 4000 x g for 1 min at room temperature, 
washing 2 x with equilibriation buffer (PBS), 2 x with activation buffer (100 mM 
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ammonium chloride), then 2 - 3 x with binding buffer of choice (200 - 400 mM phosphate 
buffer pH 4). To reduce surface tension of aqueous buffers during Hg-IMAC preparation 
and peptide enrichment, add final concentration of 10 % acetonitrile (Fisher Scientific) or 
0.001% Tween 20 (BioRad Laboratories Inc) to all buffers. Note that Tween 20 
reproducibly provided slightly better enrichment, however, must be removed prior to any 
MS analysis (either MALDI or liquid chromatography (LC/MS). Failure to remove 
residual Tween 20 results in potent suppression of peptide ions and can be a detrimental 
contaminate in LC/MS instrumentation, resulting in tedious decontamination procedures.  
Thus, we suggest to use Tween 20 only when interested in the Hg-IMAC eluant sample, as 
excess can be rinsed away during resin washing (below). If supernatant is of interest 
analytically and/or LC/MS is being employed, we advise to substitute Tween 20 for 
acetonitrile. 
Load protein digests as described above (2.2.2; 500 µL at 5 ng/µL) onto resin and 
incubate at room temperature, nutating in the dark for 60 min. Collect resin by 
centrifugation at 4000 x g, remove supernatant and store. Wash resin 3 x with wash buffer 
(10 mM phosphate buffer pH 4). Elute bound peptides 2 x with 50 µL 100 - 200 mM DTT 
shaking 30 min at room temperature and store. Concentrate both supernatant and eluant by 
rotary evaporation at 30 °C to approximately 20 - 40 µL, spot 1:1 with CHCA matrix as 
above and analyze by MALDI-TOF MS. If necessary, dilute remaining samples 1:1 with 
0.1 % TFA/water and desalt/ concentrate peptides using ZipTip® C18 pipette tips 
(Millipore Corp) as per manufacturers protocol.  Spot eluant 1:1 with CHCA matrix as 
above and analyze by MALDI-TOF MS. 
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2.2.6 Screening reversible thiol oxidation with Hg-IMAC enrichment and 4,4-
dithiopyridine labeling coupled to MS 
The devised schemes to identify candidate redox-regulated protein thiols are based 
on the merging of previously described methods with key modifications (Fig.2.4).  First, 
protein is desalted to remove excess reducing agent (DTT or equivalent), then is subjected 
to a defined molar ratio of protein: hydrogen peroxide (H2O2, ACP Chemicals Inc) for a 
defined time period.  At this time, oxidation is quenched by addition of acidic (pH ~4) 
phosphate buffer.  At this point, each individual scheme diverges; (1) a rapid proteolytic 
digest commenced by addition of an acid protease or 2) 4,4-dithiopyridine (4-DTP, Acros 
Organics) is added to block remaining free thiols.  In Scheme (1), after digestion, peptides 
are loaded onto activated Hg-IMAC resin as described above.  After incubation, 
supernatants are then divided equally, where half are reduced with TCEP, while the other 
diluted equally with water. Then both samples are loaded again onto activated Hg-IMAC 
resin as described above.  Enriched thiol-containing peptides are eluted from all three Hg-
IMAC enrichments and analyzed by MALDI-TOF MS as above to identify intrinsic redox-
regulated and redox-inactive cysteine residues.  In Scheme (2), labeled proteins are then 
neutralized with excess buffer and proteolytically digested with trypsin. These peptides are 
subsequently analyzed by MALDI-TOF MS as above. All mass spectrometry data was 
manually determined to have a peptide mass accuracy of at least ±0.3Da with further 
confirmation by MS/MS analysis. 
2.2.7 Identifying candidate redox active thiols of PTPs using Hg-IMAC enrichment  
It is important to note that these procedures will again be user-defined, and unique 
to individual proteins of study. However, we have outlined strategies herein, highlighting 
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the pertinent steps.  Some considerations must be made in order to optimize steps, which 
include the following.  Starting protein concentration and reaction volume will depend on 
individual proteins of study.  We have outlined strategies with molar ratios to ease 
conversion among researchers, however, we have used protein concentrations of 0.2 - 0.5 
µg/µL at 130 µL, but lower concentrations are also readily applicable.  Moreover, molar 
ratio(s) of protein:H2O2 and incubation time(s) are empirically determined based on a 
variety of characteristics such as number of suspected redox active thiols, physiological 
concentration ratios and detection limits.  A simple activity, DTNB or 4-DTP assay which 
titrates the redox reversibility will strongly aid in defining the starting molar ratios to be 
explored, however, a simple titration may also be applied directly to the scheme instead.  
Also, we are careful not to dilute working protein reaction volume too drastically by 
addition of H2O2. We routinely calculate addition of 20 µL concentrated H2O2 to achieve 
desired final molar ratio.  Since most reaction volumes are quite small, all pH values should 
be checked on equivalent reaction mixes containing appropriate scaled up volumes (not 
concentrations) of each pertinent component.  For small volumes of true reaction mixes, 
check the pH occasionally by spotting ~2 µL on pH paper to ensure reaction conditions are 
as expected.  
Rapidly thaw reduced protein to 0 °C, and place on ice.  Buffer exchange protein 
(130 µL) into reaction buffer (20 mM Tris-HCl pH 7.3, 25 mM NaCl or equivalent) using 
Zeba™ Desalt Spin Columns as per manufacturers protocol.  During column preparation 
for exchange, prepare stock solutions of H2O2 in reaction buffer.  Once exchanged, quickly 
transfer desired volume of protein to a suitable microcentrifuge tube and add desired 
volume of stock H2O2 to initiate oxidation reaction.  Gently mix, and incubate shaking at 
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room (or desired) temperature for defined time.  Following incubation, quench reaction to 
pH ~4 with 1 M phosphate buffer (phosphate:reaction, 1:4, v:v) to 200 mM final 
concentration. Add acidic protease (GluC, pepsin or equivalent) at 1:10 protease: protein 
ratio to initiate digestion, and incubate at 25 °C shaking for desired time. Our digested were 
routinely performed for 1 h. During digestion, equilibrate and activate an appropriate 
amount Hg-IMAC resin as described above. After digestion, add digest to activated resin, 
and incubate as described.  After 1 h, collect resin by centrifugation, remove supernatant 
and partition equal volumes into separate microcentrifuge tubes. During 1 h incubation, 
equilibrate and activate an appropriate amount Hg-IMAC resin as described above. 
Reduce one equivalent with 4 mM TCEP for approximately 10 - 20 min at 25 °C, 
while diluting the second equivalent with an equal volume of water.  After reduction, dilute 
peptide samples 1:1 with 200 mM phosphate binding buffer containing desired additive 
(10 % acetonitrile or 0.001% Tween-20). Load each of the peptide pools onto activated 
Hg-IMAC resin and incubate as described.  During incubation, wash and elute primary Hg-
IMAC resin containing redox-inactive and reduced thiols as described. Once time is met 
for secondary Hg-IMAC incubations, wash and elute as described. Analyze all samples as 
previously described. 
2.2.8 Identifying redox-induced disulfide-linked peptides of PTPs using low pH, 4,4-
dithiopyridine labeling MS 
Based on targeted thiols identified in 2.2.7, appropriate Cys to Ser point mutants 
should be made to solidify data sets. Here, we analyzed wild-type and C115S hYVH1 for 
presence of disulfide pairs among the active site cysteine and N-terminal thiols within the 
catalytic domain. 
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Rapidly thaw reduced protein to 0 °C, place on ice.  Buffer exchange protein (130 
µL) into reaction buffer (20 mM Tris-HCl pH 7.3, 25 mM NaCl or equivalent) using 
Zeba™ Desalt Spin Columns as per manufacturers protocol.  During column preparation 
for exchange, prepare stock solutions of H2O2 in reaction buffer. Once exchanged, quickly 
transfer desired volume of protein to a suitable microcentrifuge tube and add desired 
volume of stock H2O2 to initiate oxidation reaction. Gently mix, and incubate shaking at 
room (or desired) temperature for defined time.  At time, quench reaction to pH ~4 with 1 
M phosphate buffer (phosphate: reaction, 1:4, v:v) to 200 mM final concentration.  Add 4-
DTP at a 1:10 reagent: protein ratio to initiate labeling, and incubate at 25 °C shaking for 
20 - 40 min.  Labeling efficacy was confirmed by subsequent addition of IAM in the 
absence and presence of TCEP [Suppl. Fig. S2.4, S2.5] 
At time, pH was neutralized through buffer exchange of protein sample into 50 mM 
ammonium bicarbonate using Zeba desalting spin columns as per manufacturers protocol. 
Add trypsin at approximately 1:20 protease: protein ratio to initiate digestion, and incubate 
at 37 °C shaking for desired time. Our digests were routinely spotted as above every 30 
min to maximize signal: noise ratio and avoid ion suppression effects. Aliquots were taken 
at each time point and reduced with TCEP to further locate disulfide bonding pairs prior to 
spotting.  All samples were analyzed by MALDI-TOF MS as described above. 
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2. 3 Results and Discussion  
Examination of protein thiol redox status continually battles between suppression 
of non-specific thiol exchange/oxidation and efficacy of labeling conditions used in 
modification, enrichment and detection steps. The wide variety of potential redox 
modifications, most of which are labile and reversible, greatly confounds all aspects of 
their accurate analysis (31). Members of the PTP superfamily show great dynamic range 
among the redox reactions in which they can undergo, with examples representing most all 
common cellular redox modifications (14). This phenomenon acts to complicate studies 
regarding PTP redox regulation, but also to highlight the necessity for continual 
development of methods for expanding current knowledge regarding these extremely 
important contributors to signal transduction. However, an economical means for 
preliminary screening of targeted redox-active thiols within PTP superfamily members in 
vitro would enable more functional studies regarding the specific regulation afforded 
through Cys-based oxidation and of those cellular pathways potentially involved in their 
reversible regulation. 
Coupling thiol labeling/enrichment with 'bottom up' mass spectrometric techniques 
has expanded the analytic abilities for studying the vast array of redox protein 
modifications at the proteomic level (28,48-50). Moreover, recent reviews have suggested 
that the levels of protein Cys oxidation are ~10% under normal cellular conditions, while 
in response to oxidants, those levels are capable of reaching ›40% of that of total cellular 
protein Cys residues, exemplifying the redox proteome as a prevent aspect of cellular 
physiology (51). But as previously mentioned, probing redox status of peptide thiols 
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readily falls victim to formation of non-specific oxidation artefacts during both labeling 
and digestion steps, mainly due to the inherent reaction conditions (large molar excesses, 
pH ~8, extended times) (31). Common labeling agents (IAM etc.) offer very little 
affordability in monitoring reaction efficiency, and as such, put potential limitations on 
data acquisition post digestion.  These limitations are exemplified upon observing data 
from conventional tryptic protein digests obtained using classical conditions without 
previously labeling protein thiols (Fig.2.2 and Fig.2.3). Here, hYVH1 digests, spiked with 
IAM labeled digests for relative comparison, were analyzed in the presence and absence of 
TCEP after overnight digestion. One can clearly note that addition of a reductant post digest 
results in a drastic increase in reduced thiol peptide peaks relative to their IAM-labeled 
counterpart, highlighting the propensity of non-specific oxidation occurring during typical 
tryptic digestion. Thus, if labeling efficiency is limited/unknown, or a label-free analysis 
is sought, potential limitations are apparent among most existing thiol-labeling MS-based 
approaches. 
To circumvent these potential limitations among current MS-based approaches 
used to studying protein thiol redox regulation, we have devised a scheme using 
commercially available and well characterized thiol labeling reagents (Fig.2.4). Our current 
platform assesses three main aspects of the traditional work-flow; time, pH and label 
characteristics. First, decreasing time during all steps will act to limit potential non-specific 
oxidation as well as increase throughput, thus posing this as a method for rapid screening 
of candidate, reversibly oxidized/regulated, protein thiols.  
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Next, decreasing the pH (≤ 4) will further limit oxidative artefacts as thiols (-SH) 
are far less reactive than their deprotonated counterparts, thiolates (-S-) (52). Moreover, in 
combination with digestion, these moieties will become even less prone to artifactual 
oxidation, as protein thiol pKa values are largely governed by tertiary microenvironments 
which are lost during proteolytic digestion. This would be the case for the highly conserved 
active site cysteine residues characteristic of PTP superfamily members, making this 
method directly applicable to the study of such events. Also, in examples such as PTP1B 
where a stable cyclic sulfonamide is formed, acidification may also disfavor non-specific 
reactions of these spatially proximal reactants (i.e. active site cysteine with neighboring 
amide nitrogen). Acidification promotes the less-reactive catalytic thiol (-SH) form, while 
also hovering the hydrogen exchange minima of amide hydrogens among the peptide 
backbone (pH~2.5) (53). These events suggest that reaction kinetics of sulfonamide 
formation would be greatly reduced as both reactants would predominantly exist as stably 
protonated species, thus disfavoring reactivity based on their chemical state. Lastly, 
coupling these phenomena to labeling and/or enrichment strategies has further 
strengthened the proposed scheme for analysis of redox regulated thiols. Organomercurials 
have long since been known to have an extremely high affinity for thiols, reacting both 
rapidly and stoichiometrically, even displacing thiol-bonded nitric oxide through preferred 
formation of a stable mercaptide. This reactivity has a pH maximum of approximately pH 
5, exhibiting the practical applicability of these chemicals towards both low pH labeling 
and/or enrichment (56). Immobilization of such compounds has also allowed for the 
selective enrichment of target thiol-containing peptides, such as the recent application used 
in study of the S-nitroso-proteome (47,48,54).  
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Figure 2. 2. Oxidation of wide type hYVH1 thiols during trypsin digestion at neutral 
pH. Recombinant hYVH1 was subjected to an overnight trypsin digestion using a 1:25 
protein: protease ratio in 50mM ammonium bicarbonate at pH (8) 37 °C. The resulting 
tryptic peptides were analyzed by MALDI-TOF analysis in linear mode immediately or 
following reduction. (A) Minus TCEP; (B) 25mM TECP.  
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Figure 2. 3. Oxidation of C115S (C4 mutation) hYVH1 thiols during trypsin digestion 
at neutral pH. Recombinant hYVH1 was subjected to an overnight trypsin digestion using 
a 1:25 protein: protease ratio in 50mM ammonium bicarbonate at pH (8) 37 °C. The 
resulting tryptic peptides were analyzed by MALDI-TOF analysis in linear mode 
immediately or following reduction. (A) Minus TCEP; (B) 25mM TECP.  
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This ability to enrich for targets acts to decrease spectral complexity, while increasing 
signal: noise ratio, thus sensitivity and accuracy, to ease subsequent analysis. Since 
immobilized organomercurials are capable of displacing nitric oxide from S-nitrosylated 
biomolecules, a second reagent capable of rapid, stoichiometric and low pH labeling of 
thiols can be exploited to differentiate this-sub-population from alternative redox-based 
thiol modifications. Such a candidate is 4,4-dithiopyridine (4-DTP), and although the 
above features are highly uncommon for most every thiol labeling agent, they are even 
further complimented by the ability of 4-DTP to reach with free thiols quantitatively, 
forming 4-thiopyridone (4-TP), a strongly absorbing chromophore with λmax of 324 nm (ε 
= 21 400 L.mol-1.cm-1) which allows for labeling efficiency to be monitored 
spectrophotometrically (55). Furthermore, unlike other thiol-based labeling agents such as 
DTNB, as the name implies, the resultant product 4-TP contains a redox-inert thione (thio-
ketone) moiety. This molecule is thus unable to participate in additional disulfide exchange 
reactions, further exemplifying this reagent as a useful primary thiol blocking agent in 
studying redox regulation of protein thiols. 
  
65 
 
 
66 
 
 
 
 
 
 
 
Figure 2.4. Schematic workflows of Hg-IMAC-based methodology. Left) Protein of 
interest is exposed to oxidative stress, sample is then acidified to quench the reaction and 
reduce the rate of oxidation “preserving” reversibly oxidized thiols (disulfides, 
Sglutathionylated, cyclic sulfenamides, S-nitrosylated thiols etc.). A rapid proteolytic 
digest using acid proteases (i.e. pepsin or Glu C) is then performed whereby peptides are 
then passed over Hg-IMAC resin to capture any reduced or S-nitrosylated thiols. Captured 
peptides are eluted using DTT and detected by MALDI-TOF MS. Resin flowthrough is 
split into two fractions, with one fraction left untreated (oxidized thiols) and the other 
reduced with TCEP (reversibly oxidized thiols). Both fractions are then passed over fresh 
Hg-IMAC resin, resin is eluted, and eluant analyzed using MALDI-TOF MS. Peptides 
found in the reduced fraction not found in the non-reduced fraction are putative reversibly 
oxidized thiols. Right) Protein is treated as above, however, after acid quench, any reduced 
thiols are blocked with 4-DTP at low pH for 1 h. These reduced thiols have been labeled 
and can no longer participate in non-specific disulfide formation and can be differentiated 
from S-nitrosylated thiols. Moreover, the pH can be raised to 7 – 8 allowing for 
conventional protein digestion with trypsin and MALDI-TOF MS analysis. 
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Although multiple work-flows can be built on this platform, we have chosen to 
highlight one such scheme which enables analysis of both redox-inactive and redox-active 
protein thiols in a single experimental run, and infer relative kinetics/quantities of each. As 
a proof of concept, both wild-type hYVH1 and C115S hYVH1 (catalytic Cys to Ser 
mutation) digests were spiked with IAM-labeled counterparts, reduced with TCEP and 
loaded onto Mercury-Immobilized Metal Affinity Chromatography (Hg-IMAC) resin at 
pH ~3.5. Selective enrichment of thiol-containing peptides was observed; alkylated, IAM-
labeled peptides, as well as non-thiol, methionine containing peptides, remained in the flow 
through supernatant (Fig.2.5 and Fig.2.6). Moreover, mutation of the active site cysteine 
of hYVH1 resulted in loss of this corresponding peptide in the eluant, suggesting that 
intrinsic peptide composition has no effect on Hg-IMAC selectivity and peptide enrichment 
(Fig.2.6C). Furthermore, since it is possible to elute thiol-containing peptides using 
performic acid through formation of sulfoxides (SOxH) (47), taken together, these data 
suggest that Hg-IMAC is capable of selective enrichment of strictly thiol-containing 
peptides at low pH in the presence the reducing agent TCEP. To note, this enrichment 
method is also highly diverse, allowing for individual tailoring of experimental procedures. 
For example, binding is quite rapid, approaching completion in approx. 30 min, however 
this rate can be 'tuned' by altering the amount of resin and/or the amount of protein/peptide 
loaded. Moreover, binding is capable over a large dynamic buffer and pH range. For 
example, 10 % acetonitrile, Tween-20 and guanidium hydrochloride additives displayed 
no substantial effects on peptide binding or enrichment over pH values  
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Figure 2.5. Characterization of Hg-IMAC selectivity for wild type hYVH1 peptide 
thiols. Both CAM-labeled and unlabeled wild type hYVH1 were trypsin digested, mixed, 
acidified, and incubated with Hg-IMAC resin for 1 hr using acetonitrile additive. 
Supernatant was collected and bound peptides were competitively eluted using DTT. All 
samples were analyzed by MALDI-TOF MS. A) Mixed peptides before Hg-IMAC 
enrichment. B) Flow-thru supernatant showing near depletion of thiol containing peptides 
while IAM labeled peptides remain. C) Peptide eluant from Hg-IMAC enrichment showing 
selective thiol-containing peptide enrichment as CAM-labeled peptides were not detected 
in the eluant.  
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Figure 2.6. Characterization of Hg-IMAC selectivity for hYVH1 C115S peptide 
thiols. Both CAM-labeled and unlabeled hYVH1 C115S were trypsin digested, mixed, 
acidified, and incubated with Hg-IMAC resin for 1 hr using acetonitrile additive. 
Supernatant was collected and bound peptides were competitively eluted using DTT. All 
samples were analyzed by MALDI-TOF MS. A) Mixed peptides before Hg-IMAC 
enrichment. B) Flow-thru supernatant showing near depletion of thiol containing peptides 
while IAM labeled peptides remain. C) Peptide eluant from Hg-IMAC enrichment showing 
specific and selective thiol-containing peptide enrichment. Neither CAM-labeled peptides 
nor the C115S peptide were detected in the eluant. 
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ranging from approx. pH 3 - 7, highlighting the wide practical applicability of this 
methodology to a variety of experimental conditions and hypotheses (Suppl. Figs. S2.2, 
S2.3). 
Based on the above findings, we have been successful in extending this workflow 
to studying redox-regulated thiols within the catalytic domain of hYVH1 (Fig.2.4).  
Briefly, reduced hYVH1 was rapidly exchanged into neutral buffer and immediately 
stimulated with H2O2. Oxidation was next quenched by the addition of a large molar excess 
of phosphate buffer pH 3.5 to effectively drop the reaction pH to approx. pH 4.  This step 
serves a dual purpose as it is widely known that phosphate buffers act to competitively 
inhibit members of the PTP superfamily, as phosphate ions can readily occupy the active 
site (13). This provides added analytic advantages, preventing non-specific oxidation of 
the catalytic cysteine residue during subsequent sample processing through a direct 
competition with H2O2. Concomitant addition of an acid protease (GluC, pepsin or 
equivalent) initiates digestion, which is followed by an initial Hg-IMAC enrichment step. 
The flow through supernatant of this first enrichment is equally partitioned and treated with 
or without TCEP, then subjected to a second Hg-IMAC enrichment, while the initial resin 
is washed and eluted for subsequent determination of reduced, redox-inactive thiols. 
Secondary Hg-IMAC enrichments are next washed and eluted for analysis of reversibly 
oxidized, redox-active thiols. 
Of interest to our study were the redox-active thiols or reversibly oxidized thiols of 
hYVH1's catalytic domain. It was observed that indeed, hYVH1 possesses other thiols 
within the catalytic domain which undergo reversible oxidation upon exposure to H2O2 
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which were attributed to the two most N-terminal thiols (Fig.2.7A). Moreover, in the 
absence of TCEP, no peptides were observed, confirming that the initial Hg-IMAC 
enrichment went to completion, removing all redox-inactive, reduced thiols (Fig.2.7B).  To 
further confirm certainty of peptide/thiol candidates, reversibly oxidized peptides from the 
TCEP reduced Hg-IMAC enrichment experiment were alkylated using IAM.  This 
modification caused all peptides to shift by multiples of the characteristic m/z 57 increase 
for IAM modification, confirming that all enriched peptides did indeed possess intrinsic 
cysteine thiols (Fig.2.7C). This also displays that Hg-IMAC does not interact with 
disulfide-linked peptides, to again, show thiol-dependent specificity.  
As glutamic acid terminated peptides do not ionize as efficiently as those of tryptic 
descent, a secondary digest of these IAM-modified, glutamic peptides was performed to 
increase ionization efficiency as well as ease target peptide identification (Fig.2.7D).  Upon 
tryptic digestion, it clearly identifies that indeed, other catalytic domain thiols of hYVH1 
participate in reversible thiol modifications, suggesting that the redox regulation of this 
DUSP may not be limited to the previously described regulation, but instead adapt a 
disulfide exchange mechanism similar to that observed for SHP-1 and SHP-2 (19). To note, 
as with any MS-based approach, a potentially strong limitation exists within the described 
method of analysis with respect to ion suppressive effects.  One can partially alleviate these 
influences by further separation of eluted peptides prior to MS analysis by reversed -phase 
high performance liquid chromatography or equivalent separations chemistry to enhance 
individual peptide resolution. In foresight, the entire workflow has been constructed for 
adaption to high-throughput LC/MS-based platforms which would further extend the 
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analytic capabilities instrumentally, while also combating the potential limitations 
described above. 
To begin elucidation of this potential mechanism governing the redox regulation of 
hYVH1, we have adapted a novel labeling strategy involving 4-DTP as a primary thiol 
blocking agent as described above. The efficacy of this reagent as a primary thiol blocking 
agent is highlighted by its ability to block subsequent IAM labeling, a condition that can 
be, as expected, ablated by TCEP reduction prior to IAM labeling (Suppl. Figs. S2.4, S2.5). 
Although a variety of reversible modifications can be stimulated by H2O2, we suspected 
that the likely candidate was disulfide bonding based on our, and Chen et al., previous 
findings (19,23). Following our alternative scheme (Fig.2.4; right) we were able to 
calculate putative disulfide masses for potential tryptic dipeptides between the active site 
cysteine (C4) and N-terminal cysteine residues (C1 and C2).  Upon analysis, we observe 
sound evidence for the formation of a disulfide bond between the active site and an N-
terminal thiol (C4 - C2 disulfide linkage) (Fig.2.8A).  This species was ablated by addition 
of TCEP, and moreover, mutation of the catalytic cysteine to serine (C115S) also resulted 
in loss of this species, suggesting that a disulfide linkage is forming between these residues 
(Fig.2.8B and C). Surprisingly, we also observed a suspected linkage between C2 and the 
vicinal thiol C1, which was also ablated by treatment with TCEP. Overall, these findings 
have begun to provide evidence for a disulfide exchange mechanism which prevents 
irreversible thiol oxidation in a manner similar to that of SHP-1 and SHP-2 for the atypical 
DUSP, hYVH1. Current site-directed mutagenesis efforts creating serine point mutants for 
individual cysteines within the catalytic domain of hYVH1 are underway to begin detailed 
characterization of the ordered steps within this disulfide exchange mechanism.  
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Figure 2.7. Characterization of reversibly oxidized thiols in the DUSP domain of 
hYVH1. The Hg-IMAC flow through containing GluC peptides generated from 
hYVH1ΔCT1 oxidized with H2O2, was split was split into two fractions; A) +TCEP to 
observe reversibly oxidized peptides and B) -TCEP to ensure Hg-IMAC enrichment went 
to completion. C) Peptides from sample A were modified with IAM and analyzed by 
MALDI-TOF to confirm enriched peptides contained free thiols. D) IAM modified GluC 
peptides digested by trypsin and re-analyzed by MALDI-TOF to improve ionization 
efficiency. 
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Figure 2.8. Identification of novel active site disulfide linkages using 4-DTP labeling. 
hYVH1 was treated with H2O2 200:1 (H2O2: protein) followed by aid quenching. Reduced 
thiols were blocked with 4-DTP at low pH. Following 4-DTP labelling, hYVH1 was 
digested with trypsin and analyzed by MALDI-TOF MS. A) Wild type hYVH1 producing 
a set of two disulfide pairs C2-C4 and C1-C2; B) hYVH1 C115S mutant produced only 
C1-C2 disulfide peptide. C) and D) treated with 25mM TCEP to reduce disulfide peptides. 
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2.4 Conclusion  
Using a combination of low pH thiol labeling and enrichment strategies, we have 
simplified the experimental workflow during sample preparation of redox-regulated 
protein thiols. As a proof-of-concept, we have examined the redox-regulation of hYVH1 
and elucidated a potential disulfide exchange mechanism. Such an added layer of 
regulation may contribute to the ability of hYVH1 to cope with cellular insults such as 
oxidative stress (23,38). Moreover, we are currently applying this strategy to large-scale 
redox proteomics experiments of both mammalian and Daphnia pulex for investigation of 
global cellular redox regulation of PTP family members. Through coupling to mass 
spectrometry, we have integrated new additions to current thiol labeling/enrichment 
schemes used in detection of redox sensitive protein thiols including those which regulate 
the activities of PTPs. 
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2.5 Supplementary Figures 
 
Supplementary Figure S2.1. Characterization of Hg-IMAC resin. (A) DTNB standard 
curve. (B) Cysteine removal using various quantities of beads shows linear relationship 
with slope suggesting a binding capacity of 2.2 μM/mL of slurry; (C) Box plot for seven 
samples having the data extrapolated to 1 mL of slurry, showing reproducibility. 
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Supplementary Figure S2.2. Characterization of the selectivity of Hg-IMAC resin for 
wild type hYVH1 at low pH. Binding done in 400 mM phosphate pH 4.0 in the presence 
of 0.001% Tween with wild type hYVH1 (A) starting material before Hg-IMAC (B) Hg-
IMAC flowthrough supernatant; notice zip tipping did not remove all of the Tween. (C) 
Hg-IMAC eluant spotted directly in DTT.  
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Supplementary Figure S2.3. Characterization of the selectivity of Hg-IMAC resin for 
C115S hYVH1 at low pH. Binding done in 400 mM phosphate pH 4.0 in the presence of 
0.001% Tween with C115S hYVH1 (A) starting material before Hg-IMAC (B) Hg-IMAC 
flowthrough supernatant; notice zip tipping did not remove all of the Tween. (C) Hg-IMAC 
eluant spotted directly in DTT.  
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Supplementary Figure S2.4. Workflow of 4-DTP labeling controls to ensure 
specificity and completion of 4-DTP labeling technique. Protein sample is acidified, 
labeled with 4-DTP, split into two fractions and treated with or without TCEP to reduce 4-
TP labeling, then neutralized and CAM-labeled with IAM. Samples are digested with 
trypsin and analyzed by MALDI-TOF. 
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Supplementary Figure S2.5. Characterization of 4-DTP labeling specificity and 
efficiency. (A) hYVH1 + 4-DTP – TCEP + IAM shows that despite the fact there was an 
extreme excess of the second label there is no IAM modified peptides. (B) hYVH1 +4-
DTP +TCEP + IAM demonstrates that when TCEP is used to remove the 4-DTP and an 
excess of IAM is added that most of the thiol containing peptides are observed as +IAM 
peptides.    
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CHAPTER 3  
The Atypical Dual Specificity Phosphatase hYVH1 Associates with Multiple 
Ribonucleoprotein Particles 
3.1 Introduction 
The protein tyrosine phosphatase (PTP) superfamily catalyzes phosphate 
hydrolysis by way of a thiol phosphate enzyme intermediate.  The PTP superfamily can be 
subdivided into subgroups that include the receptor PTPs, intracellular PTPs, 
phosphoinositol lipid phosphatases, and the dual specificity phosphatases (DSPs) (1). 
The DSPs represent the most diverse group of PTPs.  Their name denotes the 
extended substrate specificity of the group for serine/ threonine and tyrosine phospho-
residues (2). Analogous to tyrosine phosphatases, the DSPs contain the invariant catalytic 
sequence C(X)5R and use a thiol phosphate intermediate as a catalytic mechanism (3).  The 
broader, more shallow active site pocket of DSPs compared with tyrosine-specific 
phosphatases results in stabilization of phosphoserine and phosphothreonine residues in 
addition to phosphotyrosine (4).  Members of the DSP family can be further subdivided 
into unique subgroups.  The best characterized, known as the mitogen-activated protein 
kinase phosphatases, are characterized by their specificity for the pTXpY signature 
sequence of mitogen-activated protein kinases (MAPKs) (5). Another well-characterized 
group of DSPs are the cell division cycle phosphatases (Cdc14 and Cdc25), which 
participate in regulation of the cell cycle by dephosphorylating cell cycle regulators 
including cell cycle-dependent kinases (6). Meanwhile, a subgroup known as the atypical 
DSPs, is the least characterized subgroup of PTPs.  These phosphatases lack the MAPK 
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recognition motifs and the characteristic Cdc25 rhodanese fold, and hence, are predicted 
to dephosphorylate substrates other than the MAPKs and cell cycle-dependent kinases (7). 
The atypical dual specificity phosphatase hYVH1 (also known as DUSP12) is an 
evolutionary conserved enzyme ranging from yeast to humans (8-10). Although the precise 
physiological role of hYVH1 remains uncharacterized, recent evidence indicates that 
YVH1 orthologs may be critical mediators of ribosome biogenesis (11-13), cell cycle 
regulation (14), and cell survival (15,16). Furthermore, the hyvh1 gene has been found 
significantly amplified in various cancers that have progressed to advanced stages (17-19), 
highlighting the importance of examining the biological activities of hYVH1.   
In addition to the N-terminal phosphatase domain, YVH1 family members contain 
a highly-conserved cysteine-rich C-terminal domain that is more highly conserved than the 
phosphatase domain.  The C-terminal domain of hYVH1 has been shown to coordinate 2 
mol of zinc per mole of protein, defining it as a novel zinc-binding domain (ZBD) and the 
only phosphatase known to contain such a domain. However, the lack of known hYVH1 
targets has hindered our understanding the biological significance of this unique enzyme. 
In this study, we employed affinity chromatography methods coupled with mass 
spectrometry to identify novel hYVH1-containing macromolecular structures.  Members 
of various ribonucleoprotein (RNP) complexes were identified and follow-up microscopy 
studies demonstrated for the first time that hYVH1 is a stress granule-associating protein.  
Moreover, we provide evidence that through its unique ZBD, hYVH1 represents a novel 
factor regulating stress granule disassembly.  
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3.2 Material and Methods 
3.2.1 Plasmid Constructs   
The plasmids encoding FLAG-hYVH1 variants have been described previously 
(16). Site-directed mutagenesis was performed to generate hYVH1 siRNA resistant 
variants. The forward and reverse primers used were as follows: 5’- 
GCTCTTGTGGTAGGTGGATCACACCTGCTTTTTC-3’ and 5’- 
GAAAAAGCAGGTGTGATCCACCTACCACAAGAGC-3’ for I313I and 5’- 
GAAAAAGCGGGTGTGATCCACCTACCACAAGAGC-3” and 5’- 
GCTCTTGTGGTAGGTGGATCACACCCGCTTTTTC-3’ for I313I P315P. All the 
mutants were verified by automated DNA sequencing (ACGT Corp.).  
3.2.2 Ribosome Profiling  
All solutions used for ribosome profiling were made using dithylpyrocarbonate 
(DEPC)-treated water (Sigma-Aldrich, Inc.). All sucrose solutions had a buffer 
composition of 80 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl (pH 7.4), and 1 mM DTT. 
Sucrose gradients were made by carefully layering 2 mL of a 5% sucrose buffer on top of 
2 mL of a 60% sucrose buffer in an ultracentrifuge tube (Beckman Coulter, Inc.) and 
incubating the tube on its side for 2.5 to 3hrs at room temperature. 
To prepare lysates for fractionation, ~1x107 cells were washed in PBS and were 
incubated with trypsin for 1 min to facilitate dislodging of cells.  Cells were resuspended 
in 10 mL of DMEM/F12 and collected by centrifugation at 1100 x g for 7.5 min at 4ºC.  
Following centrifugation, cell pellets were gently re-suspended in ice cold PBS containing 
100 µg/mL cycloheximide and incubated for 10 min on ice.  Following a second 
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centrifugation step, cell pellets were resuspended in 100 µL of cold hypotonic buffer (1.5 
mM KCl, 2.5 mM MgCl2, and 5 mM Tris-HCl (pH 7.4)) supplemented with 4 µL 
RNaseOUTTM Ribonuclease Inhibitor (Invitrogen) before adding 100 µL cold hypotonic 
lysis buffer (1.5 mM KCl, 2.5 mM MgCl2, 5 mM Tris-HCl (pH 7.4), 2% sodium 
deoxycholate, 2% Triton X-100, 2.5 mM DTT).  Cells were lysed by 40 strokes in a pre-
chilled Dounce homogenizer (Kontes) and centrifuged at 8000 x g for 10 min at 4ºC to 
remove cellular debris.  Total protein concentration was determined by Bradford assay, 
and lysates were supplemented with 1.7 mg/mL heparin (Sigma).  Lysate volumes 
corresponding to equal amounts of total protein (~1.5 mg) were loaded onto the sucrose 
gradient and fractionated by ultracentrifugation at 245,000 x g for 3 hrs at 4ºC.   
Following centrifugation, a 50% sucrose cushion was carefully layered on top of 
the gradient and an 80% sucrose cushion was injected through the base of the centrifuge 
tube.  The tube was capped and plumbed in line with a UV detector with a filter set to 254 
nm.  A 60% sucrose chase solution was then continuously pumped into the centrifuge tube 
at a flow rate of 1 mL/min using a BioLogic LP Chromatography System (Bio-Rad).  
Fractions corresponding to cytoplasmic RNA, intermediate fractions, 40S, 60S, 80S, and 
polysomes were collected manually and analyzed by immunoblotting as described 
previously (16).   
3.2.3 Affinity Chromatography and Mass Spectrometry  
Human U2OS osteosarcoma cells (ATCC) were grown in DMEM/F12 with 10% 
FBS and 2 mM L-glutamine and supplemented with 1% penicillin/streptomycin antibiotics 
at 37C and 5% CO2. Cells (1 X 107) were seeded in 20-cm dishes 24 h before transient 
92 
 
transfection with 10 μg of DNA (FLAG-hYVH1 or empty vector) and FuGene HD 
(Promega) following the protocol of the manufacturer.  Cells were lysed and subjected to 
FLAG-affinity chromatography as previously described (16).  Proteins were liberated from 
the FLAG resin using an elution buffer containing 0.25% SDS with 0.2% Tween-20 
adapted from Antrobus and Borner (20).  The eluant was then precipitated with acetone 
and prepared for trypsin digestion as described previously (15,16).  The pools of tryptic 
peptides were analyzed by tandem MS with a SYNAPT G2Si Q-TOF mass spectrometer 
using the ion mobility feature of the instrument for increased ion separation.  MS/MS was 
performed by data independent acquisition methods for increased peptide identification. 
MS data of three technical replicates from three biological replicates were analyzed using 
ProteinLynx Global Server software (PLGS version 3.01).  Data were further annotated 
using Excel and the software program Venny (http://bioinfogp.cnb.csic.es/tools/venny/).  
3.2.4 Immunoflorescence analysis 
U2OS cells were seeded on four-chamber slides (BD Bioscience) 24 h prior to 
transient transfection with 0.5 g of DNA using FuGene HD.  For siRNA experiments, 
cells were transfected for 48 h with control siRNA or hyvh1 siRNA according to the 
protocol of the manufacturer using Lipofectamine Raiman (Invitrogen).  For siRNA rescue 
experiments, siRNA-resistant hYVH1 variants were transfected for 24 h following siRNA 
treatment. Prior to fixation, cells were treated with or without saponin (0.1%) for 45s at 
room temperature as described previously (21,22).  Cells were then fixed for 15 min with 
3.7 % paraformaldehyde at room temperature.  Thereafter, cells were permeabilized with 
0.15% Triton X-100 for 2 min and blocked with 5 % BSA for 1 h at room temperature. 
Primary antibodies including mouse anti-FLAG (Sigma, F1804), rabbit anti-FMRP 
93 
 
(Abcam, ab17722), rabbit anti-YB-1 (Sigma, Y0271), rabbit anti-hYVH1 (10), and goat 
anti-TIA-1 (Santa Cruz Biotechnology, sc-1751) were incubated for 1 h. Following 
washes, cells were incubated with horse anti-mouse FITC (Vector, FI-2000) and goat anti-
rabbit Alexa 568 secondary antibodies (Life Technologies, A11011) for 1 h at room 
temperature.  Cells were washed and stained with Hoechst stain (0.5 mg/ml) (Invitrogen) 
for 2 min and mounted on the slide. Fluorescence microscopy was utilized to capture the 
images using a X40 objective. Pearson’s correlation coefficients and stress granule size 
were determined using Image J (National Institutes of Health) using the JACoP plugin and 
analyze particle features respectively.  Calculations were determined by analyzing at least 
30 cells from three independent experiments.  Statistical analysis was performed using the 
Student’s t-test (Excel), with differences considered statistically significant at P < 0.01.  
3.2.5 Co-Immunoprecipitation  
U2OS cells were transfected with FLAG-hYVH1 variants for 24 h and cells were 
lysed as described above.  Cellular lysates were incubated with 20 l of FLAG- Protein A 
agarose beads (Sigma) for 1.5 hrs at 4C. Immunoprecipitates were washed three times 
with 50 mM Tris-HCl (pH 7.4), 0.1% Triton X-100, 150 mM NaCl, and 0.1% SDS and 
analyzed by immunoblotting using mouse anti-FLAG (Sigma, F3165), rabbit anti-L26 
(Sigma, R0655), anti-FMRP, and anti-YB-1 as described previously (16).  Densitometry 
analysis was performed using Image J.  Data was normalized to levels of the corresponding 
FLAG-hYVH1 variant and compared with wild type FLAG-hYVH1.  P < 0.05 was 
considered statistically significant.  For direct protein-protein interaction analysis, 
recombinant hYVH1 was purified as described previously (16).  The His-FMRP construct 
was a kind gift from Dr. Utz Fischer and purification of recombinant FMRP was conducted 
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as described previously (23).  GST-YB-1 was purchased from Abnova.  Recombinant 
proteins (10 ng) were incubated for 2 h at 4C.  Protein complexes were isolated via 
immunoprecipitation and analyzed by immunoblotting as described above. 
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3.3 Results and Discussion 
3.3.1 Human YVH1 co-sediments with the 60S ribosomal subunit  
Recently, YVH1 in yeast has been identified as a novel trans-acting factor 
important for 60S ribosomal biogenesis (14,16).  Studies have suggested that YVH1 is not 
present on the mature translationally active ribosome, but required for exchanging the 
protein Mrt4 for the ribosome stalk complex (P0, P1,and P2) during late-stage 60S 
maturation (11,13). Because hYVH1 shares ~30% sequence identity with YVH1, we were 
interested in determining if the human ortholog also localizes to the 60S ribosomal subunit. 
To examine the relationship between hYVH1 and ribosomal complexes, HEK 293 cells 
expressing endogenous hYVH1 were lysed using a dounce homogenizer. Ribosomal 
subunits were sedimented on a 10% - 50% sucrose gradient by ultracentrifugation.  
Following ultracentrifugation, gradients containing sedimented particles were displaced by 
injection of a 60% sucrose chase solution through an 80% sucrose cushion (Fig.3.1A).  
RNA absorbance at 254 nm was monitored, revealing peaks corresponding to small RNA 
species, 40S, 60S, and 80S ribosomal subunits, and polysomes (80S + mRNA) and 
halfmers (40S + mRNA).  Immunoblot analysis was then performed on the fractions to 
determine the presence of hYVH1 and the 60S ribosomal subunit protein RPL26 as a 
fractionation control for the 60S and 80S subunits.  As shown in Fig.3.1B, endogenous 
hYVH1 (37 kDa) co-elutes within the 60S and 80S peak fractions (Fig.3.1A, right panel, 
top blot).  These fractions were confirmed by the presence of the large ribosomal subunit 
protein RPL26 (17 kDa) in Fig.3.1A, fourth blot, fifth and sixth lanes, corresponding to the 
60S and 80S ribosomal complexes, respectively. 
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To characterize the structural features mediating the interaction between hYVH1 
and ribosomal subunits, it was important to determine if ectopically expressed hYVH1 can 
also associate with the 60S ribosomal subunit. As shown in Fig.3.1A (right panel), no 
appreciable change occurs in the ribosome profiles in the presence of overexpressed 
FLAG-hYVH1.  Furthermore, FLAG-hYVH1 displays a similar pattern of co-fractionation 
as endogenous hYVH1. 
The presence of hYVH1 in the 80S fractions was unexpected and could be due to 
an association with the 80S complex or due to low resolution between the 60S and 80S 
peaks, as these two complexes elute very close to one another.  Thus, to increase resolution, 
smaller-volume fractions were collected for FLAG-hYVH1 samples and subjected to 
immunoblotting.  This analysis revealed that although the ribosomal core protein RPL26 
co-eluted with both the 60S and 80S fractions as expected (Fig.3.1B, bottom panel), FLAG-
hYVH1 elution was observed predominantly in the 60S fraction, with only trace levels of 
hYVH1 detected in the later fractions (Fig.3.1B, top panel).  To complement the 
fractionation data, a co-immunoprecipitation experiment was performed between hYVH1 
and RPL26 (Fig.3.1C). Immunoblot analysis shows FLAG-hYVH1 in the lysates of 
transfected cells but not in the negative control lysates (Fig.3.1C, top row).  Furthermore, 
although equal levels of RPL26 are observed in the lysates of both the negative control and 
FLAG-hYVH1 samples, only FLAG-hYVH1 was able to pull down RPL26 from cellular 
lysates (Fig.3.1C, bottom row). Collectively, these results support the notion that hYVH1 
associates with the 60S ribosomal complex in human cells, suggesting an analogous role 
as its yeast ortholog of functioning as a 60S ribosome biogenesis factor.   
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Figure 3. 1. Co-fractionation and co-precipitation of hYVH1 with 60S ribosomal 
subunits is domain dependent. A, HEK 293 cells expressing endogenous hYVH1 or 
transiently transfected with indicated FLAG-hYVH1 variants were lysed and applied to a 
sucrose gradient (10 - 50%). Absorbance (254 nm) was monitored (left panel) and fractions 
were collected by peak as shown (F1-F8), resolved by SDS-PAGE and subjected to 
immunoblots (IB) analysis (right panel). Shown are the immunoblots for each of the 
samples adjacent to its corresponding ribosome profile trace. Each trace and corresponding 
immunoblot is representative of at least three independent experiments. B, Ribosome 
profiling was repeated for FLAGhYVH1 WT, with smaller-volume fractions to better 
resolve 60S and 80S complexes. Fractions corresponding to the 60S and 80S peaks (red 
box, indicated in A) were analyzed by immunoblotting for RPL26 and FLAG-hYVH1. C, 
FLAG-hYVH1 co-immunoprecipitation (IP) with endogenous RPL26. HEK293 cells 
expressing empty FLAG vector (Control) or FLAG-hYVH1 were subjected to FLAG 
immunoprecipitation and analyzed by immunoblotting. Image is representative of three 
independent experiments. D, Schematic representation of hYVH1 deletion constructs 
analyzed in (A). Amino acid boundaries for the hYVH1 variants are shown. E, 60S 
fractionation levels of hYVH1 variants were quantitated by densitometry and normalized 
to total input levels. Means + S.D. from three independent experiments are shown. The p 
values were calculated using the Student t-test and compared to wild-type hYVH1 (**, 
p<0.05). 
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To elucidate specific regions of hYVH1 required for ribosome co-fractionation, the 
N-terminal phosphatase domain (ΔZBD) and C-terminal zinc binding domain (ΔDSP) 
(Fig.3.1D) were expressed separately in HEK 293 cells (Fig.3.1A).  Cells overexpressing 
domain deletion mutants were lysed, and ribosome profiling was performed.  Immunoblot 
analysis of lysates and fractions reveals that both domains appear to play a role in 60S 
ribosomal association (Fig.3.1A, E).  We observed little detectable co-fractionation of 
hYVH1 ΔZBD with the ribosomal subunits (Fig.3.1A, E).  Surprisingly, we also observed 
significant loss of co-fractionation when expressing hYVH1 ΔDSP.  These results reveal 
that although the ZBD is indispensable for 60S co-fractionation, the N-terminal DSP 
domain of hYVH1 is also a contributing factor for optimal ribosome association. 
3.3.2 Human YVH1 interactome analysis reveals novel RNP associating proteins  
Many ribosomal trans-acting factors exhibit extra ribosomal functions and localize 
to multiple RNPs (24).  Therefore, to explore whether hYVH1 is also present on additional 
RNP complexes, we conducted an interactome analysis in U2OS cells using FLAG affinity 
chromatography followed by tandem mass spectrometry.  We sought a cell line that was 
responsive to hYVH1 expression for our interactome analysis.  U2OS cells were selected 
because of our previously finding that hYVH1 expression in U2OS cells affects cell cycle 
progression (14). Following isolation using FLAG-hYVH1 affinity chromatography, 
isolated proteins were eluted from the resin using a “soft elution” SDS buffer adapted from 
Antrobus and Borner (20).  Eluted proteins from control cells or FLAG-hYVH1-expressing 
cells were then acetone-precipitated and processed for trypsin digestion.  The tryptic 
peptides were analyzed by LC/MS/MS in a SYNAPT G2Si Q-TOF mass spectrometer (see 
“Material and Methods” for details) for protein identification.  To increase the number of 
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proteins identified we employed the ion mobility chamber positioned between the 
quadrupole and time of flight tube within the SYNAPT instrument.  The ion mobility step 
adds an additional separation feature to the experiment, as peptides that co-elute off the 
reverse phase column will often have different mobility (drift time) through the ion 
mobility chamber.  This additional chromatography step significantly increased the number 
of proteins identified (Fig.3.2A).  Proteins of interest were those that were confidently 
identified in the FLAG-hYVH1 sample but not in the FLAG-control sample (Fig.3.2B).  
Identified proteins consisted of numerous 60S ribosomal unit proteins including the 
ribosome stalk proteins P0, and P2 (Fig.3.2B).  The high number of core 60S ribosomal 
proteins identified was expected given the fact that YVH1 in yeast has been shown to 
associate with the 60S ribonucleoprotein (RNP) particle (11-13) validating our affinity 
chromatography approach.  Surprisingly, however, large numbers of 40S subunit proteins 
were also identified.  This was unexpected because, in yeast, YVH1 has been characterized 
exclusively as a 60S biogenesis factor (11,13). In contrast, our interactome data provides 
suggestive evidence that, in human cells, hYVH1 may be present on additional RNPs that 
possess 40S subunits. Along these lines, proteins characterized for their role in translational 
repression via storage mRNPs containing 40S ribosomal subunits were also present in the 
interactome analysis, along with proteins that function in pre-mRNA splicing (Fig.3.2B).  
Collectively, this dataset implies that in addition to 60S ribosome biogenesis, hYVH1 may 
localize to multiple RNP particles important in regulating mRNA processing. 
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Figure 3. 2. Interactome analysis identifies proteins associated with various RNPs. A, 
Venn diagram highlighting the significant increase in interactome coverage using the ion 
mobility (HDMS) feature of the mass spectrometer when compared to without (TOF-MS). 
See “Material and Methods” for details. B, pie chart highlighting the distribution of unique 
proteins identified in the hYVH1 interactome among various RNP subtypes, including 
ribosome subunits (RPL3-36a and RPS2-26) and mRNP granules (FMRP and YB-1). 
Representative proteins are listed in the boxes. The interactome analysis was conducted on 
data generated from three independent experiments. Identified proteins represent proteins 
found exclusively in FLAG-hYVH1 samples and present in at least two biological 
replicates.  
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3.3.3 Human YVH1 co-localizes with FMRP and YB-1 containing granules  
Our hYVH1 interactome findings showed a large number of proteins known to 
function in RNP dynamics.  We therefore were interested in testing if hYVH1 indeed 
localizes to RNPs other than the 60S ribosome.  Of notable interest was the presence of the 
fragile X mental retardation protein (FMRP) and Y-box containing protein 1 (YB-1), both 
regulators of translation repression on mRNP granules (Fig.3.2B).  FMRP-containing 
mRNP granules have been shown to mediate transport of specific mRNAs for localized 
protein expression (24,25).  Furthermore, FMRP and YB-1 are necessary factors for 
repressing translation during transport (24,26).  To confirm that hYVH1 associates with 
FMRP/YB-1 containing foci, we analyzed their co-localization using fluorescence 
microscopy (Fig.3.3).  To better visualize FLAG-hYVH1 on RNP particles, we treated the 
cells with a low concentration of the detergent saponin (Fig.3.3A). Gentle treatment of cells 
with saponin prior to fixation and immunostaining has been shown to permeabilize plasma 
membranes, liberating soluble cytoplasmic proteins while retaining the localization of 
proteins found on suborganellar structures (27).  In the absence of saponin, the hYVH1 
localization pattern is quite diffuse, making it difficult to resolve hYVH1 association with 
subcellular structures (Fig.3.3A) (10,16). With saponin treatment we found that hYVH1 is 
readily detectable on punctate structures in the cytoplasm (Fig.3.3A).  Thus, when we 
conducted the immunofluorescence studies using saponin treatment we observed co-
localization between hYVH1- and YB-1-positive granules in the cytoplasm (Fig.3.3B). 
There were also YB-1 containing particles in the cytoplasm that were devoid of hYVH1, 
and no co-localization was detected with nuclear YB-1.  As YB-1 is a multifunctional 
protein, including a well-characterized transcriptional regulator (28-30), these results 
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suggest hYVH1 associates with selective YB-1-containing particles.  Co-localization was 
also observed between FMRP and hYVH1 (Fig.3.3C).  Similar to YB-1, co-localization 
between hYVH1 and FMRP was also observed on punctate structures in the cytoplasm, 
with no detectable co-localization of hYVH1 with the nuclear pool of FMRP.  It has been 
proposed that FMRP associates with its mRNA target in the nucleus and assists in the 
transport of mRNA into the cytoplasm for targeted mRNP transport (31).  Thus, our co-
localization pattern suggests hYVH1 association with FMRP containing granules may 
occur after the particles are shuttled from the nucleus to the cytoplasm. 
Co-immunoprecipitation experiments were performed to complement the 
immunofluorescence studies. U2OS cells expressing FLAG-hYVH1 variants were 
immunoprecipitated with anti-FLAG-agarose resin and probed for endogenous YB-1 and 
FMRP (Fig.3.4).  We observed that both wild-type hYVH1 and hYVH1 C115S (a 
phosphatase-inactive mutant) co-immunoprecipitated YB-1 and FMRP to a similar extent, 
suggesting that phosphatase activity is likely not required to associate with YB-1 and 
FMRP particles.  Regarding the modular domains of hYVH1, the ZBD of hYVH1 has been 
shown to be required, and in some instances sufficient, for the observed hYVH1-mediated 
cellular functions, such as ribosome biogenesis (11-13), cell cycle regulation (14), and cell 
survival (16).  As shown in Fig.3.4, deletion of the ZBD (hYVH1 ΔZBD) reduced co-
immunoprecipitation with both FMRP and YB-1 by ~2 fold (Fig.3.4B), although 
association was not completely abrogated.  Although immunoprecipitating equal levels of 
hYVH1 ΔDSP compared with the other hYVH1 variants was problematic, densitometry 
analysis of data normalized to FLAG-hYVH1 levels suggests that the ZBD associates with 
FMRP/YB-1 granules to a similar extent as wild-type hYVH1. It is important to note that 
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in our hands and reported by others (10), the catalytic domain alone (ΔZBD) is 
substantially more stable in vitro, and expresses at much higher levels during transient 
transfection of mammalian cell lines compared with the ZBD (ΔDSP) and full-length 
hYVH1.  Thus, the N-terminal DSP domain may help stabilize the ZBD.  Although it 
remains inconclusive if the ZBD is sufficient, we can conclude that the DSP domain alone 
maintains some ability to associate with the FMRP/YB-1 granules.  However, the ZBD 
appears to be necessary for optimal hYVH1 association with FMRP/YB-1 complexes.  
We also examined whether hYVH1 binds directly to FMRP or YB-1 in vitro using 
purified recombinant proteins and co-immunoprecipitation experiments.  Although a 
variety of conditions were tested, there was no detectable evidence that hYVH1 could 
directly associate with FMRP or YB-1.  As mRNP granules are multiprotein complexes, 
these results suggest that hYVH1 likely associates with YB-1- and FMRP-containing 
granules through a linking protein rather than directly through YB-1 or FMRP.  Future 
work utilizing cross-linking tools and proximity based mass spectrometry techniques will 
be needed to delineate the direct binding partner linking hYVH1 to FMRP/YB-1 containing 
granules. 
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Figure 3. 3. Co-localization of hYVH1 with FMRP and YB-1 containing particles. A, 
U2OS cells were transiently transfected with FLAG-hYVH1 for 24 h, left untreated or 
saponin treated, and analyzed by anti-FLAG immunofluorescence microscopy. B, Cells 
were treated with saponin and probed for FLAG-hYVH1 (green) and endogenous YB-1 
(red). C, Cells were treated with saponin and probed for FLAGhYVH1 (green) and 
endogenous FMRP (red). Regions of interest are presented in expanded views. Images 
were collected using x40 oil objectives and are representative of at least three independent 
experiments. Scale bar= 15 μm.  
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Figure 3. 4. Co-immunoprecipiatation of hYVH1 with YB-1 and FMRP complexes. 
A, U2OS cells were transiently transfected with FLAG-pCMV empty vector (EV), wild 
type FLAG-hYVH1, FLAG-hYVH1 C115S, FLAG-hYVH1 ΔZBD or FLAG-hYVH1 
ΔDSP for 24 h. Cells were lysed as described in “Material and Methods” and subjected to 
anti-FLAG immunoprecipitation (IP). Following SDS/PAGE, immunoblots (IB) were 
probed with anti-FLAG (third panel), anti-YB-1 (second panel) and anti-FMRP (upper 
panel) to detect FLAG-hYVH1, YB-1, and FMRP, respectively. Immunoblots of whole 
cell lysates are shown for the expression of FLAG-hYVH1 variants, YB-1 and FMRP. B, 
Coimmunoprecipitation of FMRP (left panel) and YB-1 (right panel) was quantitated by 
densitometry and normalized to FLAG-hYVH1 levels. Means + S.D. from three 
independent experiments are shown. The p values were calculated using the Student t-test 
and compared to wild-type hYVH1 (**, p<0.05). 
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3.3.4 Human YVH1 associates with stress granules under arsenic stress  
FMRP and YB-1 have been shown to play multiple roles in mRNP dynamics and 
regulation of translation.  One common example is their presence on stress granules.  Stress 
granules are critical RNP intermediates that temporarily store mRNAs and sequester 
proteins during cellular insults (32). FMRP overexpression is sufficient to form stress 
granules in the absence of cell stress, suggesting its prion-like folding trait is an important 
component in stress granule architecture (33). YB-1 has also been described as a stress 
granule marker (34), whereas studies have implicated YB-1 levels affect stress granule 
dynamics.  For example, a recent report demonstrated knockdown of YB-1 expression 
reduces stress granule formation because of translational regulation of factors involved in 
stress granule nucleation (35).  Given that hYVH1 has been implicated as a cell survival 
factor (16,36,37), we were interested in testing if hYVH1 co-localizes with YB-1 and 
FMRP on stress granules during cellular insults.  Thus, stress granules were induced by 
arsenic treatment, and immunofluorescence microscopy was performed to visualize co-
localization (Figs.3.5-3.6).  Furthermore, stress granule formation was confirmed by 
staining for the well-characterized stress granule marker T-cell-restricted intracellular 
antigen 1 (TIA-1) (Figs.3.5D, 3.6C).  TIA-1 is a translational repressor with 3’UTR RNA 
binding activity and is a core stress granule component because of its self-aggregation 
property (32).  To resolve hYVH1 localization to YB-1/FMRP foci, we again treated cells 
with saponin.  This treatment had to be carefully optimized since mild treatment poorly 
resolves hYVH1 at subcellular foci, whereas prolonged treatment overly permeabilizes 
cells resulting in release of stress granules. Under these conditions, we observed significant 
co-localization of wild-type hYVH1 with YB-1 and FMRP-containing stress granules 
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(Fig.3.5 A-C, 3.6A and B).  To rule out stress granule localization because of general 
protein overexpression, we examined co-localization between TIA-1 and ectopically 
expressed FLAG-MTMR2, a lipid phosphatase (38,39).  Although FLAG-MTMR2 
displays a punctate localization pattern, we detected no significant co-localization with 
TIA-1 stress granules (Fig.3.5C).  Moreover, we analyzed the domain deletion variants to 
determine the regions important for association.  Deletion of the ZBD (hYVH1 ΔZBD) had 
the most significant effect on association with YB-1/FMRP-containing granules (Figs.3.5A 
and 3.6A, center panels).  Interestingly, although association was significantly abrogated, 
there were still detectable YB-1/FMRP-containing granules that were positive for the 
ΔZBD deletion variant.  Therefore, these results again suggest a contributing role of the N-
terminal DSP domain for hYVH1 localization to the YB-1/FMRP granules.  With regards 
to the C-terminal ΔDSP variant, we did observe fewer positive cells overall due to either 
low transfection efficiency or instability as noted above. However, the cells that did express 
hYVH1 ΔDSP displayed significant co-localization to YB-1/FMRP granules, indicating 
that the ZBD is likely the principal facilitator of hYVH1 association to these particles 
(Figs.3.5 and 3.6, bottom panels).   
  
109 
 
  
110 
 
 
 
 
 
 
 
 
 
 
Figure 3. 5. Co-localization of hYVH1 and YB-1 containing particles during arsenite 
stress. U2OS cells were transiently transfected with wild-type FLAG-hYVH1, FLAG-
hYVH1 ΔZBD, or FLAG-hYVH1 ΔDSP for 24 h, exposed to 0.5 mM sodium arsenite for 
1 h, saponin treated, and analyzed via immunofluorescence microscopy. A, U2OS cells 
were probed for FLAG-hYVH1 variants (green) and endogenous YB-1 (red). B, U2OS 
cells were probed for endogenous TIA-1-containing stress granules (green) and 
endogenous YB-1 (red). C, U2OS cells were probed for the negative control FLAG-
MTMR2 (red) and TIA-1 containing stress granules. Regions of interest are presented in 
expanded views. Images were collected using a X40 objective. D, Pearson’s Correlation 
Coefficient  was utilized to quantify the extent of co-localization between YB-1 and FLAG-
hYVH1 variants. Means ±S.D. of three independent experiments (n=30 cells) is shown. 
The p values were calculated by the Student t-test and compared with wild-type hYVH1, 
with differences considered statistically significant at p values < 0.01 (**). Scale bars=15 
μm. 
  
111 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 6. Co-localization of hYVH1 and FMRP containing particles during arsenite 
stress. U2OS cells were transiently transfected with wild-type FLAG-hYVH1, FLAG-
hYVH1 ΔZBD, and FLAGhYVH1 ΔDSP for 24 h, exposed to 0.5 mM sodium arsenite for 
1 h, saponin treated, and analyzed by immunofluorescence microscopy. A, U2OS cells 
were probed for FLAG-hYVH1 variants (green) and endogenous FMRP (red). B, U2OS 
cells were probed for TIA-1-containing stress granules (green) and endogenous FMRP 
(red). Regions of interest are shown in expanded views. Images were collected using a X40 
objective. C, Pearson’s Correlation Coefficient was utilized to quantify the extent of co-
localization between FMRP and FLAG-hYVH1 variants. Means ±S.D. of three 
independent experiments (n=30 cells) is shown. The p values were calculated by the 
Student’s t-test and compared with wild-type FLAG-hYVH1, with differences considered 
statistically significant at p values < 0.01 (**). Scale bars =15 μm. 
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3.3.5 Human YVH1 expression levels modulate stress granule size  
Stress granules are transient structures (32).  The temporal regulation of stress 
granule assembly/disassembly is an inherent property, allowing for strategically controlled 
repression and restoration of translation in response to cellular insults (32). The above 
results implicate hYVH1 as a novel stress granule-associating protein. We were interested 
in confirming this finding more directly with the core marker TIA-1 and investigating the 
relationship between hYVH1 expression levels and alterations in stress granule properties.  
To this end, we analyzed the ability of hYVH1 variants to co-localize with TIA-1 in 
response to arsenic treatment and measured stress granule size as a read out for hYVH1-
mediated modulation of stress granule dynamics (Fig.3.7).  Wild-type hYVH1, as 
expected, localized to TIA-1 foci.  Interestingly, we observed that the size of the stress 
granules was significantly smaller in cells expressing hYVH1 compared to control cells 
(Fig.3.7).  The hYVH1 ΔDSP variant was also able to localize to TIA-1 stress granules, 
and, analogous to wild-type hYVH1, significantly reduced stress granule size.  The hYVH1 
ΔZBD variant also co-localized with TIA-1, although at a statistically significant lower 
level.  Moreover, hYVH1 ΔZBD failed to significantly reduce the size of TIA-1-positive 
stress granules compared with wild-type hYVH1 and the hYVH1 ΔDSP variant.  Taken 
together, these results establish hYVH1 to be a novel stress granule factor whose 
overexpression alters stress granule size/architecture.  Moreover, deletion analysis revealed 
that the DSP domain possesses moderate stress granule binding ability, with the ZBD 
domain likely the primary mediator, as this region is sufficient for the hYVH1-mediated 
effects on stress granule size. 
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Figure 3. 7. Expression of hYVH1 reduces size of TIA-1 positive stress granules. U2OS 
cells were transiently transfected with wild-type FLAG-hYVH1, FLAG-hYVH1 ΔZBD, 
and FLAG-hYVH1 ΔDSP for 24 h, exposed to 0.5 mM sodium arsenite for 1 h, saponin-
treated and analyzed by immunofluorescence microscopy. A, U2OS cells were probed for 
FLAG-hYVH1 variants (green) and TIA-1-containing stress granules (red). B, U2OS cells 
were probed for endogenous FMRP (green) and TIA-1 stress granules (red). Regions of 
interest are shown in expanded views. Images were collected using a X40 objective. C, 
Image J was utilized to quantify the mean area (pixels2/granule) of stress granules (SG). 
Means ±S.D. of three independent experiments (n=25 cells) is shown. The p values were 
calculated by the Student’s t-test and compared with control cells, with differences 
considered statistically significant at p < 0.01 (**). Scale bars=15μm 
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To rule out that localization to stress granules is unique to overexpressed hYVH1, 
we confirmed that endogenous hYVH1 localizes to TIA-1-positive stress granules under 
arsenite stress (Fig.3.8A).  We then tested if hYVH1 is required for stress granule formation 
by reducing hYVH1 expression with a validated hyvh1 siRNA (14) and quantitating the 
percentage of cells containing stress granules.  Because saponin can potentially affect stress 
granule solubilization during treatment, and considering that localization of hYVH1 was 
not the experimental objective, we did not treat cells with saponin for these experiments to 
more accurately quantitate stress granule-positive cells (Figs.3.8 and 3.9). As shown in 
Fig.3.8, knocking down the expression of hYVH1 did not significantly affect the 
percentage of cells exhibiting stress granules, suggesting that hYVH1 is not required for 
stress granule formation.  The findings that knockdown of hYVH1 expression does not 
affect stress granule formation while overexpression of hYVH1 reduces stress granule size, 
points to a possible role in promotion of stress granule disassembly. 
To further explore this hypothesis, we examined the effect of reducing hYVH1 
expression on the stress granule disassembly process (Fig.3.9).  Cells exposed to arsenite 
for 1h were washed and provided fresh media to initiate stress granule disassembly.  After 
1h or 2 h recovery periods, the percentage of cells possessing stress granules was 
determined.  Cells transfected with control siRNA possessed less stress granules at the 1-h 
(37% + 4%) and 2-h (13% + 3%) recovery time points compared with cells transfected 
with hyvh1 siRNA (73% + 7%, and 35% + 5%, respectively), consistent with the idea that 
hYVH1 is a contributing factor for stress granule disassembly.  
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Figure 3. 8. Knockdown of hYVH1 expression does not affect stress granule 
formation. A, U2OS cells were exposed to 0.5 mM sodium arsenite for 1h, saponin-treated, 
and probed for endogenous hYVH1 (green), and TIA-1 (red). B, U2OS cells were 
transfected with hyvh1 siRNA for 48h and probed for endogenous hYVH1 (green) and 
TIA-1 (red). Images were collected using a X40 objective. C, quantitation of the percentage 
of cells containing stress granules in response to hyvh1 siRNA treatment. Means ±S.D. of 
three independent experiments (n=300 cells) is shown. Each data point represents the 
percentage of 10 cells containing stress granules (SG). D, U2OS cells were transfected with 
indicated amounts of hyvh1 siRNA and control siRNA for 48h and lysed as described in 
“Material and Methods”. Whole cell lysates were probed with anti-hYVH1 and anti-actin 
antibodies. IB, immunoblot. Scale bars=15μm.  
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These results were confirmed using siRNA rescue experiments. Site-directed 
mutagenesis was employed to produce siRNA-resistant hyvh1 constructs that could be 
exogenously expressed following siRNA treatment (Suppl. Fig.S3.1 and Suppl. Fig.S3.2).  
As shown in Fig.3.9B, expression of the wild-type hYVH1 siRNA-resistant variant was 
able to effectively rescue the disassembly phenotype induced by knocking-down the 
expression of endogenous hYVH1. Moreover, we examined functional features of this 
mechanism by repeating these experiments with siRNA-resistant hYVH1 variants that 
were catalytically inactive (C115S) or expressed the domain deletion variants (Fig.3.9B, 
C).  The results show that the hYVH1 C115S mutant is as effective at rescuing the 
disassembly phenotype as wild-type hVYH1, indicating that phosphatase activity of 
hYVH1 is not required.  This conclusion was also supported by the ΔDSP sample, which 
also was able to rescue the phenotype (Fig.3.9B and C).  In contrast, deletion of the ZBD 
clearly resulted in significant failure to rescue the disassembly phenotype suggesting that 
the C-terminal ZBD is the primary region mediating the hYVH1-induced acceleration of 
stress granule disassembly.  Collectively, these results suggest that depletion of hYVH1 
expression affects the ability of cells to disassemble stress granules during recovery from 
cellular insults.  Furthermore, analogous to past studies evaluating YVH1 cellular effects 
(11-14,16), the presence of the ZBD rather than the phosphatase activity is the key 
determinant for the observed effects on stress granule dynamics. 
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Figure 3. 9. Knockdown of hYVH1 expression attenuates stress granule disassembly. 
A, U2OS cells were transfected with hyvh1 siRNA for 48h and exposed to 0.5 mM sodium 
arsenite for 1h. Cells were washed, provided fresh media, and allowed to recover for the 
indicated time before probing for endogenous hYVH1 (green), and TIA-1 positive stress 
granules (red). Images were collected using X40 objective. B, the above experiment was 
repeated in the presence of siRNA-resistant hYVH1 variants transiently transfected for 24 
h. Shown are representative cells following a 2-h recovery from arsenite treatment. An 
asterisk indicates the expression of siRNA-resistant hYVH1 variants. C, quantitation of the 
percentage of cells containing stress granules in response to hyvh1 siRNA treatment for 
the indicated recovery time. Each data point represents the percentage of 50 cells 
containing stress granules. Means ±S.D. of three independent experiments (n=150 cells) 
are shown. For the rescue experiment (B), the percentage of siRNA resistant hYVH1 
positive cells possessing stress granules was calculated. Means ±S.D. of three independent 
experiments (n=150 cells) is shown. The p-values were calculated by the Student’s t-test 
and compared with control siRNA-transfected cells, with differences considered 
statistically significant at p < 0.01 (**). Scale bars=15μm.   
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It is interesting to note that the heat shock protein HSP70 has also been implicated 
as an important disassembly factor because of its intrinsic chaperone function and ability 
to disassociate proteins from macromolecular complexes, including stress granules (40).  
HSP70 was identified in our current interactome screen but was not reported as a protein 
hit because of its low-level identification in the control sample (data not shown).  However, 
we have previously reported that endogenous hYVH1 associates with HSP70 through a 
direct interaction between the ZBD of hYVH1 and the ATPase domain of HSP70, 
suggesting the proteins exist in a functional complex (16).  Thus, it is tempting to speculate 
that hYVH1 and HSP70 may collaborate to promote stress granule disassembly during 
recovery from cell stress exposure.  We are currently examining this hypothesis along with 
elucidating mechanisms regulating hYVH1 stress granule activities. 
In conclusion, interactome analysis provided an unbiased approach toward 
discovering novel subcellular compartments containing hYVH1.  Although future detailed 
analysis will be required to fully understand the mechanism of action, our results point to 
an expanded role for hYVH1 in mRNP and stress granule regulation. We have evidence 
that recombinant hYVH1 has no detectable affinity for RNA when analyzed by the 
RNAcompete microarray technique (D. Ray, Q. Morris, T. Hughes, personal 
communication) (41,42).  This implies that hYVH1 likely targets to mRNPs through 
protein-protein interactions.  The maturation and functionality of mRNPs is regulated 
through various trans-acting factors and a wide range of mechanisms, including reversible 
phosphorylation and allosteric protein-protein interactions (21).  Thus, we are interested in 
investigating the contribution of hYVH1 toward regulating the protein complement of the 
maturing mRNPs in response to a variety of extracellular stimuli.  Moreover, FMRP/YB-
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1 expression elicits cytoprotective and cell cycle effects (22,43).  These cellular phenotypes 
are postulated to be a result of temporal translational regulation of specific mRNAs 
involved in these cellular processes. Because hYVH1 expression exhibits similar effects 
on the cell cycle and cell survival (14,16), it will be important to examine whether these 
phenotypes are the result of hYVH1-mediated effects on RNP dynamics. 
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3.4 Supplementary Figures 
 
Supplementary Figure S3. 1. Expression of FLAG-hYVH1 variants in hyvh1 
knockdown cells. U2OS cells were either transfected or not transfected with indicated 
amounts of hyvh1 siRNA for 24h before transient transfected with wild type FLAG-
hYVH1, C/S FLAG-hYVH1, FLAG-hYVH1 ΔZBD, and FLAG-hYVH1 ΔDSP for 24h. 
cells were lysed as described in “Material and Methods”. Whole cell lysates were probed 
with anti-hYVH1, anti-Flag and anti-actin antibodies. 
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Supplementary Figure S3. 2. Synonymous mutation FLAG-hYVH1 resistant siRNA. 
U2OS cells were either transfected or not transfected with indicated amounts of hyvh1 
siRNA for 24h before transient transfected with wild type FLAG-hYVH1*, C/S FLAG-
hYVH1*, FLAG-hYVH1 ΔZBD, and FLAG-hYVH1 ΔDSP * for 24h. cells were lysed as 
described in “Material and Methods”. Whole cell lysates were probed with anti-hYVH1, 
anti-Flag and anti-actin antibodies. 
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CHAPTER 4  
Structural Characterization of Dual Specificity Phosphatase hYVH1 using 
Hydrogen/ Deuterium Exchange Mass Spectrometry 
4.1 Introduction  
The atypical dual specificity phosphatase hYVH1 (also known as DUSP12) is an 
evolutionary conserved enzyme ranging from yeast to humans (1-3). Recent studies have 
demonstrated that YVH1 orthologues function in ribosome biogenesis, cell cycle 
regulation, and cell survival (4-9). Moreover, the hyvh1 gene has been found to be 
significantly amplified in various cancers that have progressed to advanced stages, 
highlighting the importance of examining the biological activities of hYVH1 (10-13). In 
addition to ribosome biogenesis, our lab has recently found hYVH1 associated with 
additional ribonucleoprotein (RNP) particles including FMRP/YB-1 mRNPs and stress 
granules by mass spectrometry (14).  HYVH1 expression levels regulated the steady state 
levels of stress granules in response to arsenite treatment, suggesting a role in stress granule 
disassembly.  Follow-up studies indicated that the zinc binding domain (ZBD) and not the 
dual specificity phosphatase (DSP) domain is required for the hYVH1-mediated effects on 
stress granule disassembly (14). However, both domains appeared to contribute to RNP 
association, emphasizing the need to acquire further structural information regarding 
hYVH1.  
X-ray crystallography studies on a truncated hYVH1 variant consisting of amino 
acids 27-189 (containing just the DSP domain) were recently published (16). It was shown 
that hYVH1 demonstrated a canonical PTP catalytic domain fold with a central β-sheet 
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surrounded by α-helices on both sides of the β-sheet (15). HYVH1 has a very similar 
structure to dual specificity phosphatase 5 (DUSP5, also known as HVH3) except for an 
additional helix (termed α6) that appears as a unique structure at the C-terminus of the DSP 
domain in the hYVH1 structure (16).  As the α6 helix does not appear to be truly a 
component of the catalytic domain, it might instead be a component of the linker region 
separating the DSP domain from the C-terminal ZBD. Furthermore, not only does the 
hYVH1 crystal structure lack the ZBD, the resolved structure is also missing the first 27 
amino acids that are required for phosphatase activity, but had to be removed for 
crystallization to be achieved (15).  
A major obstacle of X-ray crystallography is the inherent difficulty of crystalizing 
certain proteins, including full-length hYVH1. This can be due to limitations such as the 
long process of crystallization optimization and requirement of a large amount of sample 
prevent it from being used on all proteins. Moreover, the structural features of proteins 
gained from formed crystals may differ from those in solutions (16,17).  Nuclear magnetic 
resonance (NMR) is another widely used tool to study 3D structure of biomolecules 
(18,19). Although the size-limit of molecules for NMR investigation has been extended, it 
remains a challenge to study molecules larger than 40 KDa by NMR. Recently, 
hydrogen/deuterium exchange mass spectrometry (HDX-MS) has emerged as a new tool 
for characterizing conformational dynamics, and protein-protein interactions (20-22). 
HDX-MS is a complementary structural technique to X-ray crystallography and NMR. 
HDX-MS has several advantages over other structural techniques including rapid analysis, 
low amounts of sample requirement, high sensitivity, and the potential to examine 
structural properties of full length proteins, including the regions that undergo dynamic 
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conformational changes that are often not resolved with other techniques.  In HDX-MS, 
proteins are exposed to D2O containing buffer for various amounts of time followed by 
quenching in low pH buffer. Proteolysis and LC-MS is then performed to measure the 
deuterium incorporation at the peptide level.  By determining the uptake of deuterium 
within different regions of the protein, one can obtain structural information as high level 
of deuterium incorporation correlates with solvent accessibility.  In the current study, we 
performed HDX-MS on full length hYVH1 and acquired novel structural topology 
information.   
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4.2 Materials and Methods 
4.2.1 Recombinant protein purification 
Bacterial recombinant wild type hYVH1 was affinity purified as previously 
described (3,9) (Refer to Material and Methods 2.2.1). Following affinity chromatography, 
the protein preparation was further purified by anion exchange chromatography using a 
Bio-ScaleTM Mini UNOsphereTM Q Cartridge (Bio Rad, 732-4100) with buffer A (25 mM 
Tris-HCl, pH 8.0) and buffer B (25 mM Tris-HCl, pH 8.0, 1 M NaCl). Proteins were 
supplemented with 1 mM dithiothreitol (DTT), 5 % glycerol (ACP Chemicals Inc.) and 0.5 
mM phenylmethylsulfonylfluoride (PMSF), then concentrated to 0.45 mg/ml using 
centrifugal concentrator (Milipore), 0.2 µm sterile filtered, aliquoted at 200 µL, and stored 
at -80 °C until further use. 
4.2.2 Hydrogen-deuterium exchange mass spectrometry 
Samples were quickly thawed and desalted using Zeba™ Desalting spin columns 
(Pierce Biotechnology), as per manufacturer's instructions, into MilliQ water. Protein was 
diluted 1:9 in buffer (20 mM Tris-HCl , 50 mM NaCl) made in deuterium oxide (D2O, 
Sigma), and adjusted to pD = 7.0 with sodium deuteroxide (NaOD, Sigma). At predefined 
time points (10sec, 40sec, 90sec and 5 h), exchange reactions were quenched by a 1:1 
dilution with freshly made quench buffer (500 mM NaPO4 pH 2.25, 1.71 M Gdn-HCl), 
vortexed and immediately frozen in liquid nitrogen to minimize back exchange. Three 
biological replicates were performed for all time points.  All remaining steps were 
performed at 0°C, with all plasticware, columns, and solvents pre-chilled and kept at 0°C. 
Immobilized pepsin (Pierce Biotechnology) was equilibrated by two successive washes 
with quench buffer. Samples were quickly thawed and rapidly digested (1min) using 
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immobilized pepsin (Pierce Biotechnology). Sample digests were injected onto a 1.8um 
HSS T3 75μm x 150mm analytical column and analyzed by LC-MS using a 6 min linear 
acetonitrile gradient followed by electrospraying the peptides into a SYNAPT G2Si Q-
TOF mass spectrometer.  In order to increase separation of the peptides, the ion mobility 
feature of the instrument was utilized.  This permitted labeling peptides with both retention 
time and ion mobility drift time data facilitating peptide assignments. 
4.2.3 Data analysis 
ProteinLynx Global Server 3.0.1 (Waters, PLGS) was used to identify peptides of 
undeuterated hYVH1 generated from a 1 min immobilized pepsin digestion (i.e. t=0 min). 
DynamX Data Analysis software 2.0 (Waters) was used to annotate the HDX data and 
calculate deuterium uptake.  The software also provided a platform to manually decrease 
the redundancy and exclude poor quality data assignments to yield data containing peptides 
that were confidently detected in all three independent measurements. Different charge 
states of the peptides also were considered. The difference of the MW between the 
deuterium-labeled (all the labeling times) and control samples was used to determine the 
relative deuterium-uptake (ΔDi, units of Da) of each peptide. The back exchange was not 
considered since the extent of back exchange during pepsin digestion and LC separation 
was expected to be the same for each peptide. 
4.2.4 Bioinformatics analysis 
The amino acid sequence of hYVH1 (AIC50853) was obtained from NCBI 
(www.ncbi.nlm.nih.gov), the 3D structure prediction model of C-terminal zinc binding 
domain (ΔDSP) of hYVH1 was generated using Protein Homology/AnalogY Recognition 
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Engine Version 2.0 (Phyre 2) by submitting the last 148 amino acids (193-340) of hYVH1. 
The predicted 3D model of a portion of the ZBD of hYVH1 was obtained and was further 
analyzed using the Swiss-PDB Viewer (Deep View).  Structure comparison was done by 
using PyMOL viewer between the predicted 3D model and the crystal structure of the 
regulatory domain of human DHX58 (also known as LGP2, PDB code 2W4R).  
4.2.5 Plasmid constructs 
The plasmid encoding wild type (WT) FLAG-hYVH1 has been described previously (9). 
The generation of plasmids encoding FLAG- hYVH1 P272A, P272A W275A and P272A 
W275A M276A variants were performed using PCR based site-directed mutagenesis. The 
forward and reverse primers for mutant variants are as follows: P272A forward 5’- CAA 
TGT ACA TCT TAT TTC ATT GAA GCT GTA CAG TGG ATG G -3’, P272A reverse, 
5'- C CAT CCA CTG TAC AGC TTC AAT GAA ATA AGA TGT ACA TTG -3'; P272A 
W275A forward 5'- C ATT GAA GCT GTA CAG GCG ATG GAA TCT GCT TTG TTG 
GG -3', P272A W275A reverse:  5'- CC CAA CAA AGC AGA TTC CAT CGC CTG 
TAC AGC TTC AAT G -3'; P272A W275A M276A forward 5'- GAA GCT GTA 
CAG GCG GCG GAA TCT GCT TTG TTG GG -3', P272A W275A M276A reverse: 5'- 
CC CAA CAA AGC AGA TTC CGC CGC CTG TAC AGC TTC -3'. All the mutants were 
verified by automated DNA sequencing (ACGT Corp.). 
4.2.6 Immunofluorescence assay 
U2OS cells were seeded on four-chamber slides (BD Bioscience) 24 hours prior to 
transient transfection with 0.3 g of DNA using FuGene HD following manufacturer’s 
protocol. Cells were incubated for 24 h, then either treated with 0.5mM Sodium arsenate 
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for 1h or untreated before perform immunofluorescence assay. Specifically, prior to 
fixation, cells were treated with saponin (0.1%) for 45 seconds at room temperature as 
previously described (21,22). Cells were then fixed for 15 min with 3.7 % 
paraformaldehyde at room temperature. Thereafter, cells were permeabilized with 0.15% 
Triton X-100 for 2 min and blocked with 5 % BSA for 1 h at room temperature. Primary 
antibodies including mouse anti-FLAG (Sigma, F1804), goat anti-TIA-1 (Santa Cruz, sc-
1751) were incubated for 1 h at room temperature. Following three 5 min washes, cells 
were incubated with horse anti-mouse FITC (Vector, FI-2000) and donkey anti-goat 
Alexa® 568 secondary antibodies (Life Technologies, A11011) for 1 h at room 
temperature.  Cells were washed and stained with Hoechst stain (0.5 mg/ml) (Invitrogen) 
for 2 min and mounted on the slide. Fluorescence microscopy was utilized to capture the 
images using a 40X objective. Pearson’s correlation coefficients and stress granule size 
was determined using the JACoP plugin and analyze particle features of Image J (NIH), 
respectively. Calculations were determined by analyzing at least 25 cells from three 
independent experiments..  
4.2.7 Limited proteolysis of hYVH1 following H2O2 treatment 
Purified YVH1 protein was quickly thawed and desalted using Zeba™ Desalting 
spin columns (Pierce Biotechnology) eluted in reaction buffer (20 mM Tris-HCl pH 7.3, 
25 mM NaCl) as per manufacturer's instructions. 20 mM H2O2 was added to the reaction 
(H2O2: reaction, 1:4), gently mixed, and incubated shaking at room temperature for 1h. 
Buffer exchange into 50 mM ammonium bicarbonate was accomplished using Zeba™ 
Desalting spin columns as per manufacturers protocol. Proteins were digested with the 
protease GluC at 1:10 protease: protein ratio and incubated overnight at 37 °C. The pool 
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of peptides was diluted 1:1 with 0.1% TFA/ water and desalted using ZipTip® C18 pipette 
tips (Millipore Corp.) as per manufacturers protocol and then were analyzed by matrix-
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) 
for hYVH1 region identification as described previously (23).  
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4.3 Results and Discussion 
4.3.1 Structural properties of hYVH1 revealed by hydrogen deuterium exchange mass 
spectrometry 
Although a crystal structure has been reported for amino acids 27-189 of hYVH1, 
no structural information is known about the ZBD, the linker region between the DSP 
domain and the ZBD, or the N-terminal 26 amino acids that were not present in the crystal 
structure.  Thus, to examine the structural topology of full length hYVH1, HDX-MS 
analysis was conducted.  Recombinant protein was expressed and purified from E. coli and 
subjected to HDX labeling at various time points (0s, 10s, 40s, 120s and 5h). Exchange 
reactions were quenched and pepsin digestion was performed prior to MS analysis as 
described in “Material and Methods”. Pepsin digestion of hYVH1 followed by tandem 
mass spectrometry employing a 6 min acetonitrile gradient produced approximately eighty 
different peptides, with a sequence coverage of 93.8%.  After filtering out poor quality 
spectra and peptides not reproducibly detected in all replicates, we were able to detect 30 
high quality hYVH1 pepsin peptides that were detected in all three replicates during our 6 
min acetonitrile gradient performed under HDX conditions.  The acquired HDX-MS data 
was then processed for relative fractional uptake (RFU) of deuterium measurements, which 
is a measure of deuterium levels compared to undeuterated control and as a function of the 
number of possible deuterated residues in the peptide sequence.  This yielded a sequence 
coverage of 85.9% with a redundancy of 1.42% after filtering the low intensity peptides 
with the DynamX 2.0 data analysis software (Waters).  In addition to retention time, the 
ion mobility feature provided drift time signatures for each peptide, which greatly aided 
assignment of isotopic peaks during data analysis.  Fig.4.1 depicts a heat map that 
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illustrates the sequence coverage of the HDX analysis and the corresponding level of 
deuterium incorporation.  Generally speaking, much of the hYVH1 had moderate level of 
deuterium uptake (20-35% RFU) with higher levels of deuterium uptake at both the N-
terminal (peptides 2-28 and 22-40) and C-terminal (327-340) ends of the protein.   
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Figure 4. 1. HDX-MS heat map of hYVH1 with the 85.9% sequence coverage. 
Recombinant hYVH1 was subjected to hydrogen deuterium exchange-mass spectrometry 
analysis at four time points. Data was analyzed as described in “Material and Methods”. 
Light green indicates low deuterium exchange, wheat indicates medium deuterium 
exchange, red indicates highly deuterium exchange, each line indicates different deuterium 
exchange time points (10s, 40s, 120s and 5 h). 
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Within the N-terminal DSP domain we obtained HDX data for most of the catalytic 
domain except for the active site cleft, which yielded poor HDX data.  We postulate that 
this may be due to this region being buried deep in the inner core as shown within the 
crystal structure (Fig.4.3, and 16) and may be resistant to pepsin digestion.  The catalytic 
acid at position Asp84 was mapped to a low incorporating peptide (residues 76-90), ~19% 
RFU) (Fig.4.1-4.2) consistent with the crystal structure that shows this residue to be facing 
the interior of the folded domain for catalysis (16).  The most highly deuterated peptides 
in the catalytic domain were residues 131-145 (~52% RFU) and 159-173 (~68% RFU), 
which were observed in two regions near the C-terminal portion of the DSP domain 
(Fig.4.1-4.4).  Interestingly, both of these peptide regions map to a common exposed 
interface on the crystal structure (Fig.4.3).  Moreover, residues 159-173, located at the end 
of the DSP domain, may represent a region that possesses the end boundary of the DSP 
domain and the beginning of the linker region (Fig.4.3).  Along these lines, several peptides 
from the linker regions displayed differential deuterium incorporation offering insight on 
possible solvent exposed sections of the linker region (Fig.4.1, 4.4).  For example, residues 
170-177 and 178-194 showed moderately low RFU levels (~25% and 18% at 10s labeling 
respectively), while residues 198-211 incorporated relatively high levels of deuterium 
(57% at 10s, 86% at 5 hrs) (Fig.4.4).  This observation opens up the possibility that within 
the 198-211 peptide exists a solvent exposed region suitable to serve as a binding interface.  
Future work will focus on using site-directed mutagenesis and cellular assays to examine 
if this region affects RNP association and/or interaction with known binding partners.   
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Figure 4. 2. The relative deuterium uptake plots and stacked spectra of peptides 22-
40, 76-90, 131-145 and 152-162 in catalytic domain of hYVH1. Purified YVH1 protein 
was subjected to HDX reaction, analyzed with mass spectrometry and DynamX software 
as described in “Material and Methods”. A1,B1,C1 and D1 are relative deuterium uptake 
plots, x-axis indicates exposure time (min), y-axis indicates relative uptake (Da). A2,B2,C2 
and D2 are stacked spectra correspond to the left deuterium uptake plots. X-axis indicates 
m/z, y-axis indicates intensity. 
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Figure 4. 3. Location of solvent exposed regions mapped onto the crystal structure of 
the catalytic domain hYVH1 (PDB code 4KI9) (15). Light green indicates low level 
deuterium exchanged, wheat indicates medium deuterium exchanged and red indicates 
high level deuterium exchanged. 
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Figure 4. 4. The relative deuterium uptake plots and stacked spectra of peptides 159-
173, 170-177, 178-194 and 198-211 in the linker of hYVH1. Purified hYVH1 protein 
was subjected to HDX reaction, analyzed with mass spectrometry and DynamX software 
as described in “Material and Methods”. A1,B1,C1 and D1 are relative deuterium uptake 
plots, x-axis indicates exposure time (min), y-axis indicates relative uptake (Da). A2,B2,C2 
and D2 are stacked spectra correspond to the left deuterium uptake plots. X-axis indicates 
m/z, y-axis indicates intensity. 
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4.3.2 Analysis of the zinc binding domain using homology modeling and HDX-MS  
Recent studies have elucidated the crystal structure of the N-terminal catalytic 
domain (DSP) of hYVH1, revealing that hYVH1 shares a catalytic domain structure with 
other dual specificity phosphatases (15). However, most of the known biological functions 
of hYVH1 such as ribosome biogenesis, cell cycle regulation, and cell survival require the 
ZBD and not the DSP domain (4-9). Thus, it is of interest to examine the structural 
properties of ZBD of hYVH1. Initially we performed in silico homology modeling to 
predict possible three-dimensional structures of the ZBD.  This was accomplished by 
submitting the last 148 amino acids (193-340) of hYVH1 to the Phyre2 protein folding 
prediction program (24). The analysis results showed the highest homology with the B 
chain of the regulatory domain of human DHX58 (PDB code 2W4R), with a confidence 
score of 94.25%. Although the identity between human DHX58 and amino acids 210-299 
of hYVH1 is only 17%, four cysteine (Cys) residues are highly conserved between hYVH1 
and DHX58 (25).  Interestingly, this model predicts that the Cys221-Cys224 pair and the 
Cys290-Cys293 pair form a Zn coordinating centre, indicating that the His237-Cys265, and 
Cys307-Cys309 pairs would form the other Zn coordinating centre in contrast to past 
predictions (3).  The HDX-MS data found that the peptides housing the eight Zn 
coordinating residues to exhibit low to moderate deuterium uptake (Fig.4.1, 4.6).  This 
points to a pattern in which the Zn binding centres are positioned towards the interior of 
the fold, which is supported by the homology model (Fig.4.5).  Furthermore, the ZBD 
homology model (amino acids: 210-299) predicted the formation of an intriguing 
hydrophobic patch region consisting of residues Pro272, Trp275, and Met276 being solvent 
exposed and forming a potential hydrophobic interface. The HDX-MS detected 
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overlapping peptides for this region.  Residues 269-275 exhibited low incorporation of 
deuterium at the early time points (9% at 10 s), with increasing incorporation at the later 
time points (17% at 2 min, 55% at 5 h).  This is consistent with the homology model that 
shows residues FIE (269-271) pointing inwards.  In contrast residues 272-286 incorporated 
a medium level of deuteriums (32-38% RFU) (Fig.4.6), consistent with the hypothesis that 
this hydrophobic patch may form on the surface of the ZBD.   
  
148 
 
 
 
Figure 4. 5. Three-dimensional predicted model of Zinc binding domain of hYVH1. 
A, structural homology model of ZBD. The amino acids 193-340 of hYVH1 sequence was 
submitted to the Phyre2 server for homology detection followed by Swiss-PDB Viewer to 
produce the structural model (see “Material and Methods”). Solvent exposed amino acids 
of interest (Pro272, Trp275 and Met276) in hYVH1 that potentially represent protein-protein 
interaction interface are shown in red, His and Cys residues coordinates zinc are shown in 
bule. B, comparison of predicted ZBD (blue) three-dimensional structure and B chain of 
human DHX58 (red) by PyMOL viewer. C, alignment of ZBD and the regulatory domain 
of human DHX58 (also known as LGP2, PDB code 2W4R) (25). Sequences are aligned 
based on the secondary structure homology predicted by the Phyre2 server. Blue arrows 
represent β-strands, and the amino acids in bold represent amino acid identity. 
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Figure 4. 6. The relative deuterium uptake plots and stacked spectra of peptides 236-
246, 255-271, 269-275 and 272-286 in C-terminal ZBD of hYVH1. Purified hYVH1 
protein was subjected to HDX reaction, analyzed with mass spectrometry and DynamX 
software as described in “Material and Methods”. A1,B1,C1 and D1 are relative deuterium 
uptake plots, x-axis indicates exposure time (min), y-axis indicates relative uptake (Da). 
A2,B2,C2 and D2 are stacked spectra correspond to the left deuterium uptake plots. X-axis 
indicates m/z, y-axis indicates intensity. 
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Figure 4. 7. Pro272, Trp275 and Met276 of hYVH1 affect TIA-1 positive stress granule 
dynamics. U2OS cells were transiently transfected with wild type FLAG-hYVH1, FLAG-
hYVH1 P272A, and FLAG-hYVH1 P272A W275A and FLAG-hYVH1 P272A W275A 
M276A for 24 h, exposed to 0.5 mM sodium arsenite for 1h, saponin treated and analyzed 
by immunofluorescence microscopy. A, U2OS cells were probed for FLAG-hYVH1 
variants (green) and TIA-1 containing stress granules (red). Regions of interest are shown 
in expanded views. B, Image J was utilized to quantify the mean area (pixels2/granule) of 
stress granules. Means ±SD of three independent experiments (n=25 cells) is shown. P-
values were calculated by the student’s t-test and compared with control cells, with 
differences considered statistically significant at P values < 0.01 (**). C, Pearson’s 
Correlation Coefficient (PC) was utilized to quantify the extent of co-localization between 
TIA-1 and FLAG-hYVH1 variants. Means ±SD of three independent experiments (n=30 
cells) is shown. P-values were calculated by the student’s t-test and compared with wild 
type FLAG-hYVH1, with differences considered statistically significant at P values < 0.01 
(**). 
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4.3.3 Examining the role of the ZBD hydrophobic patch in stress granules dynamics 
Our interactome analysis showed that hYVH1 associates with numerous RNPs and 
regulates stress granule dynamics (14).  As the ZBD is likely the principal facilitator of 
hYVH1 association to these particles, we were interested in testing the effects of mutating 
residues that by HDX were predicted to reside in solvent exposed regions. The HDX data, 
supported by the partial ZBD homology model, provided evidence that the hydrophobic 
patch containing amino acids Pro272, Trp275, and Met276 are exposed to solvent. Therefore, 
we performed site-directed mutagenesis on these amino acids, and tested if the mutations 
affected hYVH1-mediated stress granule phenotypes using immunofluorescence cellular 
assays. To resolve hYVH1 localization to stress granules induced by arsenic stress, we 
treated cells with saponin as previously shown (14).  As expected, we observed significant 
co-localization of wild type hYVH1 with TIA-1 containing stress granules (Fig.4.7).  Also, 
the size of the stress granules was significantly smaller in expressing wild type hYVH1 
compared to control cells, consistent with what was observed previously (14). The hYVH1 
P272A and P272A W275A variants also co-localized with TIA-1 positive stress granules 
and significantly reduced the size of these granules.  However, the co-localization between 
hYVH1 P272A W275A M276A variant and stress granules was observed a slightly lower 
level, and more importantly was not as effective as wild type hYVH1 at reducing the size 
of stress granules. Interestingly, the phenotype resembles that of the hYVH1 ΔZBD variant 
(Fig.3.7).  Taken together, this result is consistent with the idea that Pro272, Trp275 and Met276 
may reside in a solvent exposed hydrophobic patch that contributes to the biological 
activities of hYVH1. 
4.3.4 Linker region undergoes conformational change in response to oxidative stress  
154 
 
 Our previous results have shown that hYVH1 forms extensive disulfide bonds in 
response to oxidative conditions (4,26), and presumably undergoes significant 
conformational changes. To test this hypothesis, we performed limited proteolysis 
experiments by digesting purified hYVH1 under native conditions with GluC with or 
without H2O2 treatment.  Generated peptides were further analyzed by MALDI-TOF-MS 
analysis to examine if the GluC hYVH1 mass fingerprint is altered in response to disulfide 
formation. Interestingly, we observed two prominent peptides at m/z 1529 and 2130 in the 
reduced hYVH1 sample (Fig.4.8A, B) that were dramatically reduced in oxidized sample 
(Fig.4.8C, D).  These two peptides correspond to amino acids 160-171 and 172-189, a 
region on the crystal structure where the DSP domain is concluding and the linker region 
begins.  Furthermore, HDX-MS analysis demonstrated that corresponding pepsin peptides 
in this linker region were among the most highly deuterated peptides in our analysis. Thus, 
we postulate that the linker region undergoes a conformational change in response to 
oxidative conditions and may represent a region that mediates regulatory control of hYVH1 
activities.  
In conclusion, HDX-MS provided novel structural insight regarding surface regions 
of full-length hYVH1.  With the knowledge that hYVH1 is a novel RNP trans-acting factor, 
it will be interesting to examine if these regions represent putative binding surfaces 
mediating protein-protein and/or protein-RNP interactions. 
  
155 
 
 
Figure 4. 8. Linker region undergoes conformational change in response to oxidative 
stress. Purified hYVH1 was treated without A, C or with B, D 20 mM H2O2 for 1h at room 
temperature before subjected to an overnight GluC digestion using a 1:10 protein: protease 
ratio in 50 mM ammonium bicarbonate pH 8, shaking at 37 °C. The pool of proteolytic 
peptides was desalted using ZipTip® C18 pipette tips before analyzed by MALDI-TOF-
MS.  
156 
 
4.4 References 
 
1. Beeser, A. E., and Cooper, T. G. (2000) The Dual-Specificity Protein Phosphatase 
Yvh1p Regulates Sporulation, Growth, and Glycogen Accumulation Independently 
of Catalytic Activity in Saccharomyces cerevisiae via the Cyclic AMP-Dependent 
Protein Kinase Cascade. Journal of Bacteriology 182, 3517-3528 
2. Guan, K., Hakes, D. J., Wang, Y., Park, H.-D., Cooper, T. G., and Dixon, J. E. (1992) 
A Yeast Protein Phosphatase Related to the Vaccinia Virus VH1 Phosphatase is 
Induced by Nitrogen Starvation. Proceedings of the National Academy of Sciences 
of the United States of America 89, 12175-12179 
3. Muda, M., Manning, E. R., Orth, K., and Dixon, J. E. (1999) Identification of the 
human YVH1 protein-tyrosine phosphatase orthologue reveals a novel zinc binding 
domain essential for in vivo function. The Journal of biological chemistry 274, 
23991-23995 
4. Bonham, C. A., and Vacratsis, P. O. (2009) Redox Regulation of the Human Dual 
Specificity Phosphatase YVH1 through Disulfide Bond Formation. Journal of 
Biological Chemistry 284, 22853-22864 
5. Kemmler, S., Occhipinti, L., Veisu, M., and Panse, V. G. (2009) Yvh1 is required 
for a late maturation step in the 60S biogenesis pathway. The Journal of cell biology 
186, 863-880 
6. Kozarova, A., Hudson, J. W., and Vacratsis, P. O. (2011) The dual-specificity 
phosphatase hYVH1 (DUSP12) is a novel modulator of cellular DNA content. Cell 
Cycle 10, 1669-1678 
7. Liu, Y., and Chang, A. (2009) A mutant plasma membrane protein is stabilized upon 
loss of Yvh1, a novel ribosome assembly factor. Genetics 181, 907-915 
8. Lo, K. Y., Li, Z., Wang, F., Marcotte, E. M., and Johnson, A. W. (2009) Ribosome 
stalk assembly requires the dual-specificity phosphatase Yvh1 for the exchange of 
Mrt4 with P0. The Journal of cell biology 186, 849-862 
9. Sharda, P. R., Bonham, C. A., Mucaki, E. J., Butt, Z., and Vacratsis, P. O. (2009) 
The dual-specificity phosphatase hYVH1 interacts with Hsp70 and prevents heat-
shock-induced cell death. The Biochemical journal 418, 391-401 
10. Biernacki, M. A., Marina, O., Zhang, W., Liu, F., Bruns, I., Cai, A., Neuberg, D., 
Canning, C. M., Alyea, E. P., Soiffer, R. J., Brusic, V., Ritz, J., and Wu, C. J. (2010) 
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes 
antigens that are expressed on CML progenitor cells. Cancer research 70, 906-915 
11. Kresse, S. H., Berner, J. M., Meza-Zepeda, L. A., Gregory, S. G., Kuo, W. L., Gray, 
J. W., Forus, A., and Myklebost, O. (2005) Mapping and characterization of the 
amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH. 
157 
 
Molecular cancer 4, 39 
12. Mendrzyk, F., Korshunov, A., Benner, A., Toedt, G., Pfister, S., Radlwimmer, B., 
and Lichter, P. (2006) Identification of gains on 1q and epidermal growth factor 
receptor overexpression as independent prognostic markers in intracranial 
ependymoma. Clinical cancer research : an official journal of the American 
Association for Cancer Research 12, 2070-2079 
13. Cain, E. L., Braun, S. E., and Beeser, A. (2011) Characterization of a human cell 
line stably over-expressing the candidate oncogene, dual specificity phosphatase 12. 
PloS one 6, e18677 
14. Geng, Q., Xhabija, B., Knuckle, C., Bonham, C. A., and Vacratsis, P. O. (2016) The 
Atypical Dual Specificity Phosphatase HYVH1 Associates With Multiple 
Ribonucleoprotein Particles. Journal of Biological Chemistry  
15. Jeong, D. G., Wei, C. H., Ku, B., Jeon, T. J., Chien, P. N., Kim, J. K., Park, S. Y., 
Hwang, H. S., Ryu, S. Y., Park, H., Kim, D. S., Kim, S. J., and Ryu, S. E. (2014) 
The family-wide structure and function of human dual-specificity protein 
phosphatases. Acta crystallographica. Section D, Biological crystallography 70, 
421-435 
16. Feng, W., Pan, L., and Zhang, M. (2011) Combination of NMR spectroscopy and 
X-ray crystallography offers unique advantages for elucidation of the structural 
basis of protein complex assembly. Science China Life Sciences 54, 101-111 
17. Yee, A. A., Savchenko, A., Ignachenko, A., Lukin, J., Xu, X., Skarina, T., 
Evdokimova, E., Liu, C. S., Semesi, A., Guido, V., Edwards, A. M., and Arrowsmith, 
C. H. (2005) NMR and X-ray crystallography, complementary tools in structural 
proteomics of small proteins. Journal of the American Chemical Society 127, 
16512-16517 
18. Kay, L. E. (2005) NMR studies of protein structure and dynamics. Journal of 
magnetic resonance (San Diego, Calif. : 1997) 173, 193-207 
19. Mittermaier, A., and Kay, L. E. (2006) New tools provide new insights in NMR 
studies of protein dynamics. Science (New York, N.Y.) 312, 224-228 
20. Guttman, M., and Lee, K. K. (2016) Isotope Labeling of Biomolecules: Structural 
Analysis of Viruses by HDX-MS. Methods in enzymology 566, 405-426 
21. Konermann, L., Pan, J., and Liu, Y. H. (2011) Hydrogen exchange mass 
spectrometry for studying protein structure and dynamics. Chemical Society 
reviews 40, 1224-1234 
22. Rand, K. D., Zehl, M., and Jorgensen, T. J. (2014) Measuring the 
hydrogen/deuterium exchange of proteins at high spatial resolution by mass 
spectrometry: overcoming gas-phase hydrogen/deuterium scrambling. Accounts of 
chemical research 47, 3018-3027 
23. Juris, S. J., Shah, K., Shokat, K., Dixon, J. E., and Vacratsis, P. O. (2006) 
Identification of otubain 1 as a novel substrate for the Yersinia protein kinase using 
158 
 
chemical genetics and mass spectrometry. FEBS Lett 580, 179-183 
24. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015) 
The Phyre2 web portal for protein modeling, prediction and analysis. 10, 845-858 
25. Pippig, D. A., Hellmuth, J. C., Cui, S., Kirchhofer, A., Lammens, K., Lammens, A., 
Schmidt, A., Rothenfusser, S., and Hopfner, K. P. (2009) The regulatory domain of 
the RIG-I family ATPase LGP2 senses double-stranded RNA. Nucleic acids 
research 37, 2014-2025 
26. Bonham, C. A., Steevensz, A. J., Geng, Q., and Vacratsis, P. O. (2014) Investigating 
redox regulation of protein tyrosine phosphatases using low pH thiol labeling and 
enrichment strategies coupled to MALDI-TOF mass spectrometry. Methods 65, 
190-200 
 
 
 
 
 
 
  
159 
 
CHAPTER 5  
General Discussions, Conclusions, and Future Directions 
5.1 Novel redox method of investigation of protein tyrosine phosphatase redox regulation 
Reactive oxygen and nitrogen species (ROS/RNS) function as signaling molecules 
at regulated low concentrations while inducing cellular stress responses at higher 
concentrations. Numerous protein tyrosine phosphatases (PTPs) have been found to be 
targets of ROS/RNS (1-3). The nucleophile cysteine residue which is necessary for PTP 
catalytic activity is very susceptible to oxidation.  Therefore, thiol oxidation acts as a form 
of temporal and reversible PTP regulator, where oxidation leads to the inactivation of the 
PTP. Since PTPs affect numerous signaling pathways, redox regulation is of critical 
importance (4). Although redox regulation of PTPs has been studied intensely recently, the 
non-specific oxidation of cysteines during sample preparation remains an analytical 
challenge.  
Thus, our lab developed a low pH, thiol labeling technique incorporating mercury 
immobilized affinity chromatography enrichment strategies combined with mass 
spectrometry to examine thiol redox dynamics (5). With this method, we provided 
additional evidence that hYVH1 utilizes a disulfide exchange mechanism to regulate its 
activity during oxidative conditions (5,6).  However, for this to be a routine tool to study 
redox regulation, we need to apply this technique under more physiological conditions.  
Future studies will likely begin with cell culture, to test if we can measure differences in 
thiol oxidation under various conditions. If successful, this technique will represent a useful 
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approach to study a broad range of cysteine-based enzymes including other members of 
the PTP family. 
5.2 Human YVH1 associates with ribonucleoprotein particles and regulates stress 
granule dynamics 
Ribonucleoprotein particles (RNPs) are diverse and highly dynamic complexes 
containing RNA, numerous RNA-binding proteins and other proteins.  Ribosomes, 
mRNPs, stress granules, and the splicesome are examples of various RNPs. Recently our  
interactome results showed that hYVH1 associates with multiple proteins which are 
components of RNPs (7). hYVH1 co-sediments with 60S ribosomal subunit and co-
immunoprecipitates with RLP26 which is the 60S ribosomal core protein (7). In addition, 
it was found hYVH1 interacts with numerous 60S ribosomal unit proteins including the 
ribosome stalk proteins P0, and P2, indicating that hYVH1 associates with the 60S 
ribonucleoprotein (RNP) particle analogous to the yeast orthologue (7-9). 
Using mass spectrometry, co-immunoprecipitation and immunofluorescence, we 
have provided evidence that hYVH1 interacts with particles containing YB-1 and FMRP, 
both of which are components of mRNPs, and regulates mRNA translation. Previously 
studies showed that YB-1 and FMRP are stress granule markers (7,10,11), and we found 
hYVH1 co-localized with YB-1- or FMRP-containing stress granules under arsenic stress. 
We have further shown evidence that hYVH1 reduces the size of stress granules without 
affecting the formation of stress granules using siRNA. In addition, expression of the C-
terminal zinc binding domain of hYVH1 (ZBD) is equally as effective at reducing stress 
granules size as wild type hYVH1 (7). The siRNA rescue experiments point to a role for 
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hYVH1 as a novel stress granule factor, with the ZBD domain being the primary region 
mediating the hYVH1 stress granule disassembly phenotype (7). In the immediate future 
our laboratory plans to further investigate the mechanism of how hYVH1 regulates stress 
granule disassembly.  To begin we would like to directly image the stress granule dynamics 
in living cells in response to hYVH1 expression to observe hYVH1 expressing cells 
disassemble stress granules in real time.  This would best be done with inducible stable cell 
lines (to overexpress hYVH1 or siRNA towards hYVH1), to correlate stress granule 
disassembly rates with hYVH1 expression.  
It has been reported that hYVH1 gene amplification is observed in numerous late 
stage cancers (12-14). We found hYVH1 associates with the ribosome and stress granules, 
leading us to hypothesize that hYVH1 might help cancer cells survive by increasing 
disassembly of stress granules or other mRNPs, leading to the release of translational 
repressors, facilitating the recovery of mRNA translation following stress (e.g. 
chemotherapy exposure), and thus preventing cancer cells from entering the apoptosis 
process. However, the mechanism of hYVH1 in stress granule dynamics is still unclear. 
Therefore, more investigations need to be done in the future to elucidate the mechanism of 
stress granule dynamics regulated by hYVH1. Heat shock protein Hsp70, the binding 
partner of hYVH1, has been implicated as an important stress granule disassembly factor 
and cancer promoter, suggesting that hYVH1 might collaborate with Hsp70 in stress 
granule disassembly process (15,16). Thus, it would be very insightful to further investigate 
the role of hYVH1 and Hsp70 interaction in stress granule disassembly.  
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Although we identified numerous binding complexes of hYVH1 from our 
interactome analysis, we did not find the direct hYVH1 binding partner or substrates of 
hYVH1. Proximity-dependent biotin identification (BioID) technique has been 
demonstrated to be a very useful method in interaction partners and substrates 
identification, particularly in regards to identification of weak or transient interactions (17-
20). BioID relies on the fusion of protein of interest with biotion ligase enzyme BirA 
mutant (BirA*), which is able to biotinylate proximal proteins (17-19). Therefore, utilizing 
the BioID technique to identify the binding partner(s) and substrate(s) of hYVH1 is a 
promising approach for advancing our understanding of hYVH1 physiological functions. 
5.3 Examination of structural properties of the atypical dual specificity phosphatase 
YVH1 using hydrogen/deuterium mass spectrometry  
Although many research groups have attempted to crystallize hYVH1, only a 
partial portion of the catalytic domain of hYVH1 has been elucidated (21). However, most 
of the physiological functions of hYVH1 found so far require the C-terminal ZBD 
(9,16,22). We examined the structural properties of full length hYVH1 using hydrogen-
deuterium exchange mass spectrometry (HDX MS). HDX offers complementary structural 
information to X-crystallography and nuclear magnetic resonance spectroscopy (NMR) in 
protein structural studies. Coupled with structural homology modeling, Pro272, Trp275, and, 
Met276 of hYVH1 were suggested to be solvent exposed. Site-directed mutagenesis studies 
indicated these three amino acids may also be involved in hYVH1-mediated stress granule 
dynamics.  The effects are similar to ΔZBD (amino acids 1-191), suggesting that hYVH1 
interacts with stress granules or mRNP in multiple sites, besides using Pro272, Trp275 and 
Met276.  
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Moreover, the region of amino acids 160-189 of hYVH1 was accessible for GluC 
digestion under reduced conditions but largely attenuated during H2O2 oxidation of 
hYVH1. These results indicate that the three-dimensional structure of hYVH1 is different 
between reduced and oxidized environments. Thus, it would be very insightful to further 
compare the structural properties of reduced and oxidized hYVH1 using hydrogen 
deuterium exchange mass spectrometry.  
Compared with other dual specificity phosphatase crystal structures, amino acids 
169-191 of hYVH1 demonstrated to possess an extra α-helix suggesting this helix is 
actually a part of the linker region (Fig.5.1) (21). In addition, ΔZBD (which still contains 
the extra α-helix) was shown partially colocalized with stress granules. Moreover, HDX-
MS analysis showed that specific regions of the linker region incorporate relatively high 
levels of deuterium. Thus, it is tempting to speculate that determinants within amino acids 
160-189 may mediate the association of hYVH1 with RNPs including stress granules. 
Examination of this hypothesis in the future would be very helpful to better understanding 
the mechanisms regulating hYVH1 stress granule activities and the boundary of domains 
of hYVH1.  
Therefore, based on all our findings, our working model proposes a collaboration 
between hYVH1 and other protein(s) in stress granule disassembly during recovery from 
cellular stress.  Specifically, zinc binding domain (ZBD) and linker region together mediate 
the localization of hYVH1 to stress granules, hYVH1 recruits other protein(s) to induce 
stress granule disassembly.  Once hYVH1 is oxidized by H2O2, the conformation of 
hYVH1 changes, leading to stress granule docking sites and protein-protein interaction 
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regions within ZBD and linker region buried. Thus, disrupts the interaction between 
hYVH1 and other protein(s) and attenuates stress granule disassembly (Fig. 5.2). 
Therefore, we are interested in further examining the mechanisms regulating stress granule 
activities, including determining the regions mediate protein-protein interactions, hYVH1 
direct binding partners, and its implication on mRNA dynamics and overall cell survival. 
 
 
 
Figure 5.1. Amino acid boundaries for the hYVH1 domains. The crystal structure of 
hYVH1 is from Jeong, D. G., Wei, C. H., Ku, B., Jeon, T. J., Chien, P. N., Kim, J. K., Park, 
S. Y., Hwang, H. S., Ryu, S. Y., Park, H., Kim, D. S., Kim, S. J., and Ryu, S. E. (2014) 
The family-wide structure and function of human dual-specificity protein phosphatases. 
Acta crystallographica. Section D, Biological crystallography 70, 421-435 (20). 
"Reproduced with permission of the International Union of Crystallography" 
(http://journals.iucr.org).   
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Figure 5.2. Proposed working model of hYVH1 in stress granule disassembly. HYVH1 
recruits other proteins to disassemble stress granules. While H2O2 can induce 
conformation change, leading to stress granule docking sites and protein-protein 
interaction regions of hYVH1 buried inside, thus disrupt hYVH1/ other proteins interaction 
and attenuate stress granule disassembly.  
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APPENDICES 
APPENDIX A-Plasmid constructs of different length of ZBD and BirA-Flag wild type 
hYVH1 
Gene of Interest Vector Expression   
 
ZBD 220-340 
pNTAP No 
pCMV Yes 
pGEX-4T-1 Yes 
ZBD203-340 pNTAP No 
pCMV Yes 
pGEX-4T-1 Yes 
ZBD192-340 pNTAP No 
pGEX-4T-1 Yes 
ZBD169-340 pNTAP No 
pCMV Yes 
pGEX-4T-1 Yes 
WT hYVH1 pcDNA5-pcDEST-BirA-Flag Yes 
 
Appendix-Table A. 1. Plasmid constructs of hYVH1. All the constructs were verified 
by automated DNA sequencing (ACGT Corp.) 
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Appendix-Figure A. 1. Expression of different ZBD variants in mammalian cells. Hela 
cells were transiently transfected with FLAG-pCMV empty vector, wild type FLAG-
hYVH1, FLAG-hYVH1 ZBD220-240, FLAG-hYVH1 ZBD203-340, FLAG-hYVH1 
ZBD192-340 or FLAG-hYVH1 ZBD169-340 for 24h. Cells were lysed as described in 
Chapter 2 “Material and Methods”. The whole cell lysates are shown for the expression of 
FLAG-hYVH1 variants (top panel) and actin (bottom panel). 
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Appendix-Figure A. 2. Affinity chromatography purification of recombinant ZBD of 
hYVH1 from bacterial expression system. pGEX-4T-1 ZBD169-340 and pGEX-4T-1 
ZBD192-340 were expressed in BL21 (DE3) and purified as described in Chapter 2 
“Material and Methods” .Lines 2-5 are  the supernatant, pellet, flowthrough and eluent of 
ZBD169-340. Lines 6-9 are the supernatant, pellet, flowthrough and eluent of ZBD192-
340. 
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Appendix-Figure A. 3. Immunoprecipiatation of BirA-Flag hYVH1. U2OS cells were 
transiently transfected with pcDNA5-pcDEST-BirA-Flag empty vector and wild type 
hYVH1 pcDNA5-pcDEST-BirA-Flag, for 24h. Cells were treated with 10M Biotin 6h after 
transfection, lysed as described in “Material and Methods” and subjected to anti-
strepavidin immunoprecipitation. Following SDS/PAGE, immunoblots were probed with 
anti-FLAG (upper panel), anti-streptavidin (second panel). Immunoblots of whole cell 
lysates are probed with anti-actin for sample loading control.  
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